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CypA:    Cyclophilin A 
HIV-1:    Human immunodeficiency virus type 1  
IN:    Integrase  
LEDGF/p5:   Lens epithelium derived growth factor p75 
PPIA:    Peptidyl propyl isomerase A 
PSIP1: proprotein convertase 4 (PC4) or splicing factor, 
arginine/serine-rich 1  (SFRS1) interacting protein 1 
(PSIP1) 
SN:    Seronegative 
SNP:    Single nucleotide polymorphism 
SNP number: Since rs numbers are too long, I chose to identify the SNPs 
analyzed here as SNP numbers so that they can fit in the 
figures 
TRN-SR2:   Transportin-SR2 
TNPO3:   Transportin 3 
SP:    Seropositive 






Humans differ substantially with respect to susceptibility to human immunodeficiency 
virus type 1 (HIV-1) infection and disease progression. This heterogeneity is attributed 
to the interplay between the environment, viral diversity, immune response and host 
genetics. This study focused on host genetics. We studied the association of single 
nucleotide polymorphisms (SNPs) in peptidyl prolyl isomerase A (PPIA), transportin 3 
(TNPO3) and PC4 or SFRS1 interacting protein 1 (PSIP1) genes with HIV-1 infection 
and disease progression.  These genes code for Cyclophilin A (CypA), Transportin-SR2 
(TRN-SR2) and Lens epithelium derived growth factor/p75 (LEDGF/p75) proteins 
respectively, which are all validated HIV replication cofactors in vitro. 
 
Methods 
One SNP A1650G in the PPIA gene was genotyped in 168 HIV-1 negative and 47 
acutely infected individuals using polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP). 6 intronic and 2 exonic haplotype tagging (ht) SNPs 
(rs13242262; rs2305325; rs11768572; rs1154330; rs35060568; rs8043; rs6957529; 
rs10229001) in the TNPO3 gene, 4 intronic ht SNPs (rs2277191, rs1033056, 
rs12339417 and rs10283923) and 1 exonic SNP (rs61744944, Q472L) in the PSIP1 
gene were genotyped in 195 HIV-1 negative and 52 acutely infected individuals using 
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TaqMan assays. The rs1154330, rs2277191, rs12339417 and rs61744944 were further 
genotyped in 403 chronically infected individuals. CypA and LEDGF/p75 messenger 
RNA (mRNA) expression levels in peripheral blood mononuclear cells (PBMCs) were 
quantified by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The 
impact of the Q472L mutation on the interaction of LEDGF/p75 with HIV-1 integrase (IN) 
was measured by AlphaScreen. 
 
Results 
The minor allele (G) of SNP A1650G (1650G) in the promoter region of PPIA was 
significantly associated with higher viral load (p<0.01), lower CD4+ T cell counts 
(p<0.01) and showed a possible association with rapid CD4+ T cell decline (p=0.05). 
The 1650G was further associated with higher CypA expression post HIV-1 infection. 
The minor allele (G) of rs1154330 in the intron region of TNPO3 was associated with 
faster HIV-1 acquisition (p<0.01), lower CD4+ T cell counts, higher viral load during 
primary infection (p<0.05) and rapid CD4+ T cells decline (p<0.01). The minor allele (A) 
of rs2277191 (rs2277191A) in the intron region of PSIP1 was more frequent among 
seropositives (p=0.06). Among individuals followed longitudinally, rs2277191A was 
associated with higher likelihood of HIV-1 acquisition (p=0.08) and rapid CD4+T cell 
decline (p=0.04) in the recently infected (primary infection) cohort. In contrast, the minor 
allele (C) of rs12339417 (rs12339417C) also in the intron region of PSIP1 was 
associated with higher CD4+ T cell counts during primary infection. The rs12339417C 
was also associated with slower rate of CD4+ T cell decline (p=0.02) and lower mRNA 
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levels of LEDGF/p75 (p<0.01). Seroconverters had higher preinfection mRNA levels of 
LEDGF/p75 compared to nonseroconverters (p<0.01) and these levels decreased after 
HIV-1 infection (p=0.02). The Q472L mutation showed approximately 2-fold decrease in 
the association constant (Kd), suggesting stronger binding to HIV-1 integrase. Our 
findings demonstrate, for the first time, that genetic polymorphisms in the TNPO3 and 
PSIP1 genes may be associated with susceptibility to HIV-1 infection and the disease 
progression. These data provide in vivo evidence that TRN-SR2 and LEDGF/p75 are 
important host cofactors for HIV-1 replication. This is also the first study to show the 
association of genetic polymorphisms in the PPIA gene with disease outcome in a 
population (South African) with high burden of HIV-1 infection. 
 
Conclusions 
Genetic variation in HIV-1 replication cofactors may be associated with disease 
outcome in a South African population. These data strongly support the role of these 
HIV replication cofactors in disease pathogenesis in vivo and suggest that these factors 
are possible targets for therapeutic interventions.  However, these data will need to be 
replicated in larger cohorts to confirm the effect of these genetic variants.  Further 
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In1981, the Centers for Disease Control and Prevention (CDC) reported that 3 hospitals in 
Los Angeles, California in the United States had been treating 5 active homosexual young 
men for Pneumocystis carinii pneumonia, for the period October 1980 – May 1981. These 
patients also had a laboratory confirmed cytomegalovirus (CMV) infection and Candida 
mucosal infection. These infections are known as opportunistic infections since they occur in 
immunocompromised patients. At about the same time, another CDC report mentioned 26 
cases of Kaposi‟s sarcoma among homosexual males, and that eight had died within 2 years 
of diagnosis [1]. The term “acquired immune deficiency syndrome” (AIDS) was used for the 
first time in 1982 to describe this disease, which was suspected to have been caused by an 
infectious agent transmitted sexually or through contaminated blood or blood products. A 
year later (1983), Luc Montagnier‟s group from the Institut Pasteur, Paris, France, discovered 
the human immunodeficiency virus type 1 (HIV-1) as the infectious agent that causes AIDS 
[2] and this was confirmed by two other independent research groups [3, 4]. 
 
More than 25 million people have died of AIDS since 1981 and there are still increasing 
numbers of people living with HIV. 33.4 million people were estimated to be living with HIV in 
2008, which was 20% higher than the number in 2000 and a prevalence of approximately 
threefold higher than in 1990 (http://www.unaids.org). This report estimated that 2.7 million 
new infections occurred in 2008. The increasing number of people living with HIV could be 
explained by a combined effect of continued high rates of new HIV infections in addition to 




Interestingly, UNAIDS 2010 epidemiological data reported that the number of new infections 
had fallen by 19% since 1999, the year in which it is thought that the epidemic peaked, 
globally (http://www.unaids.org). This report also states that of the estimated 15 million 
people living with HIV in low- and middle- income countries who need treatment today, over 
one third of them have access–translating into fewer AIDS deaths. Although the 
epidemiological estimates appear to suggest that the HIV epidemic has stabilized, sub-
Saharan Africa remains the region most heavily affected by HIV, accounting for most new 
HIV infections and world‟s AIDS-related deaths in 2010.  
 
Females continue to be affected disproportionately by HIV in sub-Saharan Africa, accounting 
for approximately 60% of estimated HIV infections in this region [5]. Social, legal and 
economic disadvantages contribute towards this high HIV infection rate observed in females. 
The world‟s response to HIV/AIDS has grown and improved considerably over the past three 
decades. However, universal access to antiretroviral treatment, prevention and continuous 





1.1 An overview of HIV-1 infection 
HIV-1 is a retrovirus belonging to the lentiviral subfamily. Lentiviruses consist of non-
oncogenic retroviruses that are characterized by long incubation periods and persistent 
infection. Like all retroviruses, HIV-1 is an enveloped positive strand RNA virus that 
replicates through inserting its DNA intermediate into the host cell genome [6].  
 
HIV-1 envelope is composed of a lipid bilayer of the host-cell membrane origin, gained during 
the budding process, and viral envelope glycoprotein (Env). The glycoprotein is formed of 
heterodimers, each containing a gp120 subunit on the outside of the membrane and a 
transmembrane gp41 subunit. Together, the two Env subunits mediate viral entry with the 
gp120 subunit being responsible for binding to the receptor (CD4) and coreceptor (CCR5 or 
CXCR4) on the host cell, and gp41 is needed for subsequent fusion of the viral and cellular 
membranes. The inside of the HIV-1 envelope is lined by units of matrix (MA) protein, helping 
to anchor the gp41 and gp120. HIV-1 is composed of two copies of single-stranded RNA 




Figure 1.1. Cross-sectional diagram of the HIV-1 virion organization. 
 
These two RNA copies are associated with the nucleocapsid (NC) proteins (p7 and p6) that 
protect the RNA from digestion by nucleases. Viral enzymes reverse transcriptase (RT), 
protease (PR) and integrase (IN) are also found within the CA (fig. 1.1). In addition, HIV-1 
contains accessory proteins: viral protein R (Vpr); negative regulatory factor (Nef); and virion 






Figure 1.1.1. HIV-1 genome organization. 
 
The largest three genes of HIV-1 transcribed are the gag, pol, and env. Gag is processed 
into proteins that make up the core of the viral particles, which are MA, CA, NC, and p6 
proteins. Envelope proteins, gp120 and gp41, are derived from the Env polyprotein, whereas 
the Pol polyprotein is processed into viral enzymes, PR, RT and IN that are encapsulated 
into the core of a virion particle. The other genes encode accessory proteins Vif, Vpr and Nef 
which are also found in the virion core (fig. 1.1.1). Several cellular proteins have also been 
detected in the virion [9].  
 
HIV-1 accessory proteins play important role to ensure efficient and productive HIV-1 
infection. The function of HIV-1 Vif is to suppress a potent antiviral host mechanism mediated 
by apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) [10]. 
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Molecular block or absence of Vif impairs replicative capacity of HIV-1 meaning that HIV-1 
requires Vif for effective viral spread in host cells, particularly in primary CD4+ T cells, the 
natural targets of HIV-1 infection [11]. Nef is expressed abundantly during the early stages of 
HIV-1 infection and is important for replication and progression to AIDS. Nef has three main 
functions: (1) Nef changes the signalling pathways of host cells by interacting with tyrosine 
and serine/threonine kinases, (2) Nef increases the infectivity of the virus after cell entry and, 
(3) Nef decreases the expression of CD4 and major histocompatibility complex class I (MHC 
I) antigens on the surface of infected cells by interacting with the components of endocytic 
machinery [8]. The molecular mechanism of Nef-mediated down regulation of CD4 may be 
important for optimal virus replication and may facilitate the release of virions.  
 
Viral protein R (Vpr) plays an important part in two unusual aspects of the interaction 
between HIV-1 and the host cell. Vpr prevents infected cells from proliferation, by interfering 
with normal cell-cycle control, and it collaborates with the MA to enable HIV-1 to enter the 
nucleus of nondividing cells [12, 13]. The induction of G2 cell cycle arrest by Vpr is thought to 
indirectly enhance viral replication by increasing transcription from the long terminal repeat 
(LTR).  
 
Tat is the transactivating protein of HIV-1 LTR for the retroviral replication. In the presence of 
Tat for transactivation, the efficiency of HIV-1 genome transcription is a hundred-fold higher 
than that of the non-Tat-activated ones [4]. The Tat protein has also been shown to play a 
crucial role in AIDS pathogenesis by inducing neurotoxicity in AIDS patients contributing to 
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the development of HIV-associated dementia [14]. HIV-1 Tat also deregulates cytokines 
expression in the immune cells, induces apoptosis in neuronal cells, and interacts with other 
cellular factors to favour its own survival [15]. These processes may inadvertently develop a 
favourable environment for opportunistic infections [16]. Rev stabilizes the viral unspliced and 
single spliced RNA and promotes its export from the nucleus by binding to the Rev 
responsive element (RRE), a specific RNA structure found in the env coding region [17]. Vpu, 
the smallest of the proteins encoded by HIV-1, is the transmembrane protein that interacts 
with the CD4 molecule in the rough-endoplasmic reticulum (RER), resulting in its degradation 
via the proteasome pathway [18]. 
 
1.2 HIV-1 Subtypes 
HIV-1 is classified into M, N, O and P groups. M group represents the major group of HIV-1 
strains and it accounts for more than 90 percent of HIV-1 infections worldwide [19]. Groups 
N, O and P are not spread worldwide but mainly confined to West and Central Africa [20-22]. 
A hallmark of lentiviruses is their extensive genetic variability due to the high error rate of the 
reverse transcriptase enzyme, the recombinogenic properties of the diploid viral genome, 
and the fast turnover of the virions in HIV-1 infected individuals. This characteristic of 
lentiviruses culminates in many strains and subtypes within the same type (reviewed in [23]). 
 
The subtypes of group M are classified into: A-D, F-H, J-K and circulating recombinant forms 
(CRFs). Subtype B of HIV-1 is most common in Europe, America, Japan, Australia and some 
Asian countries, while subtype A, C and D are more common in Africa. The other subtypes F, 
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G, H, J and K are rare but spread through Africa, South America, and some parts of Europe. 
When a naïve cell is coinfected with two viruses of different subtypes, the genetic material of 
both viruses may mix during the replication process resulting in a new viral strain called a 
circulating recombinant form (CRF) [21]. Virus mutation and replication are likely to result in 
new HIV genetic subtypes and CRFs. 
 
1.3 The overview of the HIV-1 Replication Cycle. 
HIV-1 infect and replicate in CD4+ T cells, dendritic cells and macrophages thereby 
functionally impairing immune cells resulting in immune deficiency [24]. The replication 
process of HIV-1 starts with the entry of the virus into the host cell through the attachment of 
the viral gp120 to the cellular CD4 receptor. This interaction induces conformational change 
of gp120, enabling it to bind to a co-receptor, CCR5 or CXCR4. This binding triggers another 
conformational change in the gp140/gp120/co-receptor complex, enabling the fusion 
between the virus and the host membrane resulting in the HIV-1 core being released into the 
cytoplasm (reviewed in [25]). This is followed by the synthesis of viral copy DNA (cDNA) from 
the viral RNA genome, through reverse transcription.  
 
Reverse transcription takes place within the reverse transcription complex (RTC), constituted 
by infecting virion core proteins, cellular proteins and the viral RNA genome [26, 27]. 
Following the completion of viral cDNA synthesis, the RTC matures into the pre-integration 
complex (PIC) [28]. The PIC then migrates towards the nucleus, probably by using cellular 




At the nuclear membrane, the viral PIC has to transverse through the nuclear pores which 
allow the diffusion of ions and molecules smaller than 9 nm in diameter. However, the 
diameter of the PIC is 56 nm [30] which grossly exceeds the diffusion limit (reviewed in [31]). 
Surprisingly, HIV-1 PIC is actively transported during interphase, reflecting its ability to 
efficiently infect non-dividing cells [32, 33]. Although a number of HIV-1 proteins that 
constitute the PIC have been implicated in nuclear import because they carry sequences that 
may serve as nuclear localization signals (NLS) [34, 35], this field of HIV-1 biology remains 
relatively muddled. 
 




The PIC associates with the host chromosomes upon nuclear entry, at which point the viral 
cDNA is integrated. From this point on, the provirus remains part of the cellular genome as 
long as the cell survives. The provirus resides latently in the cell, forming a viral reservoir; 
alternatively, activation of transcription of viral genes can initiate the formation of the new 
virions. When transcription starts, multiple spliced mRNA encoding Tat, Rev, and Nef 
proteins necessary for enhanced and efficient HIV-1 replication get produced. Binding of Tat 
to the LTR boosts HIV transcription due to the assembly of processive transcription 
complexes of the LTR promoter. Rev allows nuclear export of full-length genomic RNA, as 
well as singly spliced mRNA, resulting in the production of Gag, Pol and Env.  
 
The viral proteins and genomic RNA assemble into newly formed particles at the cellular 
membrane which contains the expressed envelope proteins. Immature viral particles bud 
from the cellular membrane or in endosomes that release the viral particles upon fusion of 
the endosome with the cellular membrane. The viral particles maturate outside of the cell 
which involves proteolytic processing of the viral Gag, and Gag-pol polyproteins by the viral 
protease (reviewed in [36]). 
 
Lentiviral infections persist lifelong as a function both of their ability to integrate their genome 
into the host chromosome and their ability to evade host immunity [36]. Their ability to evade 
host immunity may be due both to high mutation rates, and to their ability to infect the 




1.4 Natural History of HIV Infection 
HIV-1 infection proceeds through different phases (fig. 1.4) starting with the acute phase of 
infection, which is characterized by rapid viral replication and spreading, which is usually 
accompanied by a symptomatic period of disease. Following the acute phase of infection is a 
latent period (viral set point), during which the virus is brought into equilibrium of replication 
and relative immune control and no disease occurs. The last phase of infection is the chronic 
phase. It is during this phase where high levels of viral replication resume at some later time, 
resulting in disease [37]. 
 
Figure 1.4. Dynamics of peripheral blood CD4+ T cell counts and plasma viral load during a 
typical course of HIV infection. The three major phases of infection are shown: acute, 




Damages caused by lentiviruses accumulate slowly over time and lead to the destruction of 
the immune system, making victims vulnerable to opportunistic infections. This is the AIDS 
stage of the disease that ultimately leads to death of the infected person. Once these people 
reach a CD4 counts below 200 cells/mm3 of blood they are then diagnosed as having AIDS 
and are at risk of developing serious opportunistic infections such as Pneumocystis carinii 
pneumonia (PCP), Mycobacterium avium complex (MAC), and cytomegalovirus (CMV) [3, 
37].  
 
1.5 Interindividual variability in susceptibility to HIV-1 infection and disease   
progression 
HIV-1 has been the most thoroughly studied virus since its discovery, but the accumulated 
knowledge has not afforded researchers the ability to design therapeutic or prophylactic 
interventions that will halt the AIDS pandemic. The intensive study of HIV-1/AIDS has found 
differences between individuals in susceptibility to HIV-1 infection and disease progression 
(reviewed in [39]). This variability is attributed to the complex interplay between the virus, 
host genetics, immune response and environment (fig. 1.5). 
 
HIV-1 has a small genome of only 9 genes (fig.1.1.1), which encode 15 proteins as a result of 
post-translational cleavage.  Due to this limited genome, the virus relies on human proteins 
referred to as HIV-1 replication cofactors for productive infection [40-42]. Previous research 
on HIV-1 and host genetics has revealed numerous human gene variants that modulate the 
host response to HIV-1 exposure [43-45]. Human genetic variation offers a partial 
explanation why some HIV-1 infected individuals maintain undetectable levels of viral load 
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(less than 50 copies viral RNA per ml) and experience a prolonged course of HIV-1 infection 




Figure 1.5.Complex interplay between virus, host (genetics and immune response) and the 
environment. 
 
The availability of genome-wide approaches represents a change in paradigm for complex 
genetic traits; however, most of the information on host genetic factors that modulate HIV-1 
has been obtained from candidate gene studies. The candidate gene study approach has 
been used to analyze allelic variants in genes that are known or suspected to be involved in 
HIV-1 pathogenesis and immune response.  Therefore most genetic markers relevant to HIV-
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1 disease identified using this approach are related to genes that are classified into one of 
the two categories: (1) HIV-1 replication cofactors, host genes coding proteins that are 
implicated in HIV-1 replication cycle and (2) restriction factors, immune related genes coding 
for innate and adaptive immune response factors as well as proteins involved in immune 
regulation and in specific anti-retroviral defense mechanism (reviewed in [46]). 
 
1.5.1 HIV-1 cell entry:  chemokine receptors 
Protection against HIV-1 infection is provided by genetic variation in the CC chemokine 
receptor 5 (CCR5) gene, which encodes the coreceptor for macrophage-tropic (R5) strains of 
HIV-1 expressed on CD4+ T-cells. Deletion of 32 base pairs (Δ32) in the coding region of 
CCR5 gene confers protection against infection by R5 strains in homozygous and delayed 
disease progression in heterozygous individuals for this allele [47-50].  
 
Chemokines are natural ligands for the same receptors hijacked by HIV-1 for cell entry. 
Therefore chemokines can have an effect on HIV-1 entry into the target cell by either 
competing with the virus for coreceptor binding or reducing the expression of the coreceptor 
on the cell surface by inducing their internalization. A number of chemokines have been 
reported to contain genetic polymorphisms that play a role in differential susceptibility to HIV-




Polymorphisms in the CCL5 gene that codes for RANTES, the CC chemokine, have been 
shown to inhibit HIV-1 replication in vitro, modulate the expression levels of RANTES and 
reduced expression was shown to accelerate disease progression [51, 52]. Other 
polymorphisms in the regulatory regions of CCL5 have been shown to affect susceptibility to 
HIV-1 infection and disease progression [53-57]. Polymorphisms in the CCL3 gene, 
macrophage inflammatory protein 1 α (MIP1α) were shown to be associated with 
susceptibility to HIV-1 infection and disease progression [55, 58]. Low copy numbers of 
CCL31 gene (MIP1αP) were shown to have detrimental effect on HIV-1 outcome [59, 60]. 
Stroma-derived factor 1 (SDF-1) on the other hand is the natural ligand for CXCR4, the 
coreceptor hijacked by CXCR4-using HIV-1 strains (X4) for entry into the target cells. 
Although polymorphisms in the 3‟-untranslated region of the SDF-1 gene have been reported 
to have various effects on HIV-1 disease outcome [61-65], however, these data could not be 
replicated [66]. 
 
1.5.2 Intracellular viral and host protein interaction 
Post cell entry, HIV-1 continues to interact with numerous host proteins with some proteins 
acting as antiviral (restriction) factors, restricting HIV-1 replication while HIV-1 replication 
cofactors enhance productive HIV-1 infection (fig. 1.5.2). HIV-1 exploits numerous human 
proteins in order to successfully complete its replication cycle and have a productive 
infection, as demonstrated by small interfering RNA screens [67-69]. Human genes that code 
for HIV-1 replication factors are ideal candidate genes for genetic variants that modulate HIV 
infection and many of these genes have been investigated in host genetic studies using 




Host genetic studies investigating the association between specific gene variants and HIV-1 
outcomes have been conducted predominantly in the populations from the developed 
countries (United States of America and Europe), mainly Caucasian populations. The focus 
of HIV-1 host genetic studies over the past 15 years, have revealed that genetic variants of 
specific genes modulate HIV-1 pathogenesis. Two of the genes whose variants have been 
confirmed to modulate HIV-1 pathogenesis include peptidyl propyl isomerise A gene (PPIA) 
which encodes the Cyclophilin A protein (CypA) and tumor susceptibility gene 101 (TSG101).  
Figure 1.5.2.The interplay between HIV-1 and cellular proteins during HIV-1 life cycle. 
Cellular proteins that promote HIV-1 replication in the host cell are indicated in green and 




TSG101 protein interacts with HIV-1 Gag, P6 protein specifically, and plays a pivotal role in 
the budding process of new viral particles from the plasma membrane of infected cells. Two 
polymorphisms (-T183C and +A181C) in the regulatory region of the TSG101 gene were 
shown to be associated with viral load and disease progression measured by CD4+ T cell 
decline [61, 71]. CypA interacts with HIV-1 capsid protein and as a result gets incorporated 
into the virion particle. Although the exact mode of action which CypA uses to promote HIV-1 
infection is not well elucidated, one theory postulated that CypA is involved in the uncoating 
process of the viral core [72]. Variants in the regulatory region of the PPIA gene have been 
shown to influence CD4+ T-cell depletion and possibly susceptibility to infection [71, 73, 74]. 
Genetic variants in restriction factors such as APOBEC3G and TRIM5α that potently inhibit 




It is important to note that bulk of the information on the association between host genetics 
and HIV-1 disease outcome have been obtained from studies of immune response genes. 
The most consistent and prominent association identified in HIV-1 host genetic studies are 
those between human leukocyte antigen (HLA) genes and disease outcome. HLA molecules 
are expressed at the cell surface where they present antigenic epitopes, viral epitopes to 
CD8+ T cells, thereby initiating the cytotoxic T cell response. Three genes (HLA-A, HLA-B 




The HLA genes are the most polymorphic genes in the human genome, with HLA class I 
genes presenting an extreme allelic diversity. The potency of elicited immune response in an 
individual infected by HIV-1 is determined by the viral epitopes that their HLA alleles are able 
to present to CD8+ T cells. Some HLA alleles such as HLA-B*57, and to a lesser extent HLA-
B*5801, have been reported to control HIV-1 and be associated with slower progression to 
AIDS in several studies [83-85]. In addition, genome-wide association study reported an 
association between HLA-B*57 and a lower viral set point [54]. Some HLA alleles are thought 
to be population specific, with B*5701 observed almost exclusively in the Caucasian and 
B*5703 being common in individuals of African ancestry.  
 
It is important to note that a SNP that is a surrogate for HLA-B*5701 showed the strongest 
association with HIV-1 viral control or long term non-progression [86-88]. HLA-B*27 has also 
been reported to restrict HIV-1 similar to HLA-B*57 [89, 90]. However, other HLA-B alleles 
such as HLA-B*35Px, are associated with rapid progression to AIDS [91, 92]. The 
associations observed between HIV-1 control and haplotypes in the major histocompatibility 
complex (MHC) and HLA supertypes [93-97] could be due to individual alleles that are 
included in these groups and to the linkage disequilibrium structure of the MHC region. 
Hence, HLA molecules can present different HIV-1 epitopes that result in immune response 
with differential restriction of HIV-1 by CD8+ T cells. 
 
Previous studies have shown that the homozygosity in HLA-A, HLA-B and/or HLA-C gene 
results in restricted (or fewer) epitopes recognized by cytotoxic T lymphocytes and 
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accelerated disease progression [91, 98]. Genetic variation in HLA-C gene has also been 
shown to be associated with viral control and gene expression [87, 99], suggesting that HLA 
class I molecules play a central role in efficacy of the immune response in certain individuals. 
 
1.5.3.1 Killer cell immunoglobulin-like receptors 
In addition to playing an important role in acquired immunity processes, HLA molecules are 
also ligands for killer cell immunoglobulin-like receptors (KIRs). KIRs are expressed on the 
surface of natural killer (NK) cells and regulate the activation of NK cells through inhibitory or 
activating signaling. NK cells constitute an integral part of the innate immune defense 
mechanism against viruses by directly killing virus infected cells and/or producing cytokines. 
 
Interaction between some HLA molecules and KIRs commonly referred to as HLA-KIR 
combination, influence HIV-1 clinical outcomes [100]. For examples KIR3DL1 and KIR3DS1 
expressed as allelic variants of the same locus on chromosome 19, both protect against 
disease progression when existing in combination with HLA-B molecules that have a Bw4 
serological specificity. Various combinations of inhibitory KIR3DL1 alleles and HLA Bw4 
molecules have been associated with lower HIV-1 viraemia and slow disease progression 
[101]. Likewise, the activating allele KIR2DS1 has been associated with lower viraemia and a 
delayed progression to AIDS when found alone [102], or in combination with HLA Bw4 
molecules that have an isoleucine at position 80 (Bw4-80I) [103, 104]. Functionally, KIR3DS1 
has been shown to correlate with strong inhibition of HIV-1 replication [105] and with higher 




Association studies of the influence of human genetic variation on HIV-1 replication may 
reveal the essential in vivo host factors that interact with HIV-1 and their epidemiologic 
importance at the population level. However, this approach has been used mostly in studies 
conducted in populations from developed countries and of European origin and yet there are 
genetic differences between populations of different origin [107].  
 
1.6 Genes that influence HIV-1 clinical outcomes differ according to populations 
Modern humans originated from  Africa about 100,000-200,000 years ago, subsequently 
migrated out of Africa to the rest of the world about 50,000 years ago and this human 
dispersal shaped the human genome by evolutionary and historical forces [108-113]. 
Therefore, allele and haplotype diversity in the non-African populations is believed to have 
been caused by migration out of Africa, followed by rapid expansion of human populations 
[114-116]. In addition, periodic outbreaks of deadly infectious agents and regional 
environmental pressures have modified the genetic architecture of disease gene allelic 
variation in local human populations [117, 118]. Genes required for reproductive and 
housekeeping functions remained conserved, whereas genes required for immunity and 
homeostasis display different alleles among different ethnicities. Allele diversity in the genes 
involved in immunity may be caused by the fact that these genes encode factors required by 
pathogens for completion of their lifecycle. Therefore these genesunder selective pressures 




The best evidence for the influence of human pathogens on natural selection comes from 
studies of host genetic resistance to Malaria. Malaria became endemic 6000–10 000 years 
ago while AIDS emerged within the last 30 years [117, 118, 120-123]. Malaria is responsible 
for most deaths among children and pregnant women. The selective pressure exerted by 
Malaria over 300–500 generations has resulted in adaptive shifts in the allele frequency of 
several genes with a role in Malaria resistance [117, 124-126]. These genes show 
geographical differences in allele frequencies correlated with the occurrence of Malaria. 
Given that HIV-1/AIDS is too recent, only three decades old, to have caused an adaptive shift 
in the allele frequency of genes involved in HIV-1 infection, Slatkin et al. modeled the effects 
of HIV-1-mediated selection for resistant CCR2 and CCR5 genotypes, predicting a modest 
2–4 year increase or decrease in survival for South Africa, a country of high HIV-1 
prevalence [127, 128]. Their model projected that within 100 years, resistance genotype 
frequencies will increase from 40 to 53% while the susceptible genotypes will decrease from 
20 to 10%, leading to a mean increase in AIDS-free survival from 7.8 to 8.8 years. 
 
HIV-1 replication cofactors are increasingly being targeted for antiretroviral therapy, yet there 
is very little information on genetic variation in these cofactors and their impact if any on HIV. 
Studies on human genetic factors that affect HIV/AIDS pathogenesis have focused mainly on 
host immune factors as discussed above (in section 1.5.3). Therefore there is a need to 
explore other biomedical interventions that may be pursued. This study examined the effect 
of genetic polymorphisms in select validated HIV-1 replication cofactors on susceptibility to 
HIV-1 infection and disease progression, shifting the focus from immune factors. An overview 
of HIV-1 replication cofactors Cyclophilin (CypA), Transportin-SR2 (TRN-SR2) and Lens 
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epithelium derived growth factor p75 (LEDGF/p75), which were the focus of this study, is 
given below. 
 
1.6.1 Cyclophilin A (CypA) modulate early post-entry HIV-1 replication outcomes 
CypA, also known as peptidyl prolyl isomerase A (PPIA) belongs to a large family of proteins 
known as the cyclophilins. By convention, we refer to the protein as CypA and the gene as 
PPIA. This family of proteins is defined by a conserved sequence of 150 amino acids that 
form an eight-stranded β-barrel with a hydrophobic pocket that serves as the binding site for 
cyclosporin and HIV-1 Gag [129-131]. Although the exact biochemical function in cells of the 
core cyclophilin domain is unknown, CypA is presumed to play a role in maintaining proper 
protein conformation. This function is inferred from the fact that cyclophilins catalyze the cis-
trans interconversion of peptide bonds N-terminal to proline. This activity has been shown to 
stimulate the rate of refolding of model proteins in vitro [132, 133].  
 
CypA is a cytosolic protein that binds HIV-1 CA and this interaction results in the 
incorporation of CypA into virion particles [134-137]. Previous studies have demonstrated the 
CypA promotes HIV-1 infectivity in target cells classifying this protein as HIV-1 replication 
cofactor [138, 139]. Given the role of cyclophilins in a cell, it is suspected that CypA regulates 
the conformation of HIV-1 Gag. Further studies were conducted to elucidate the functional 
role of CypA in HIV-1 infection [140-144]. These studies relied largely on the use of 
mutations in gag or competitive inhibitors such as cyclosporin to block the Gag-cyclophilin 
interaction. However, neither of these experimental conditions abrogates the interaction 
completely and both potentially can cause pleiotropic effects [145]. A third confounding issue 
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is the number and abundance of cyclophilins in mammalian cells; at present there are 15 
known human cyclophilins and nearly all have the capability to bind HIV-1 Gag [134, 135].  
 
Braaten and Luban produced cell lines depleted for PPIA (PPIA-/- Jurkat T-cell lines), which 
helped in demonstrating that CypA is required for wild-type replication kinetics of HIV-1 and, 
more specifically, for the infectivity of HIV-1 virions [145]. However, none of the 14 other 
known cyclophilins substituted functionally for CypA in PPIA-/- Jurkat cells [145]. These data 
demonstrated that CypA is important for HIV-1 replication kinetics in vitro. 
 
The PPIA-/- Jurkat cells did not produce virions that had significant biochemical abnormalities, 
which was in keeping with previous studies where the Gag-cyclophilin interaction was 
disrupted using Gag mutations or cyclosporin [134, 137, 141, 142]. Noticeably, virions 
produced by PPIA-/- cells were defective at an early stage of the virus life cycle. However, 
these data did not pinpoint the exact stage of HIV-1 replication at which CypA acts. Virions 
produced under conditions that blocked the Gag-CypA interaction exhibited normal 
endogenous reverse transcriptase activity in vitro [141]. This could suggest that virion-
associated CypA might be required during the process of virion uncoating [146], or virion 
binding or fusion to target cells [142]. However, these data do not rule out the possibility that 
the defect observed before the start of reverse transcription is a consequence of CypA 
deficiency during the preceding virion assembly process.  
 
Current data on the mode of action of CypA in the HIV-1 life cycle suggests two possible 
roles that CypA may play in HIV-1 infection. Some data points to CypA playing a crucial role 
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post cell entry, during the uncoating process while the other data suggests its involvement in 
cell attachment. These two theories are discussed in the following sections. 
 
1.6.1.1 The role of CypA in the HIV-1 replication cycle 
Cyclophilin A is incorporated into nascent virions by specifically binding to the CA domain of 
the Gag precursor during HIV-1 assembly [129, 134]. Preventing CypA-packaging, either by 
the addition of cyclosporin A (CsA) to producer cells or by the introduction of mutations in the 
binding region of CA, inhibits virus infectivity, demonstrating a strict requirement for CypA in 
HIV-1 replication [134, 137]. As aforementioned, these CypA-deficient viruses are identical to 
wild-type (WT) particles and the observed block of infectivity of CypA-deficient virus has been 
mapped prior to the initiation of the viral reverse transcription into target cells [141].  
 
CA dissociates from the viral nucleoprotein complex shortly after entry [147], suggesting that 
unfolding (or uncoating) of the CA is necessary for productive infection. Given the cellular 
function of CypA, researchers have proposed that CypA induces HIV-1 uncoating in a 
manner similar to that of the chaperone heat shock protein in the uncoating of clathrin from 
coated vesicles [146]. It is suggested that CypA facilitates the proper disassembly of the shell 
of CA molecules which protects the viral genome. However, anti-CypA antibodies block HIV-
1 entry suggesting that CypA does not exclusively serve to uncoat the viral genome, it also 
play a role during HIV-1 entry [143]. 
 
In order to delineate the role of CypA in HIV-1 entry, researchers used viruses that lack CypA 
to establish whether these viruses fail to enter target cells. Interestingly, a preponderance of 
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evidence directly implicated CypA in HIV-1 entry [142]. Viruses that lacked CypA were 
unable to attach to target cells [148]. The data that demonstrated that anti-CypA antibodies 
prevent HIV-1 replication by blocking the initial step of infection, viral adsorption, further 
confirmed the role of CypA during cell entry. 
 
The latter finding suggests that CypA incorporated into the virion localize at the viral surface. 
Corroborating this hypothesis, anti-CypA antibodies immobilized to a solid phase can capture 
WT viruses but fail to capture CypA deficient viruses [142]. Given that host CypA is 
specifically incorporated into virus particles via an interior viral protein (Gag), data from 
Saphire et al. suggests that it must subsequently relocate to the surface of the virus [142]. 
This exposure of CypA at the viral surface is consistent with its suspected role in mediating 
HIV-1 attachment to the cell surface. 
 
1.6.1.2 The mode of action of CypA in the HIV-1 life cycle during attachment 
Based on its peptidyl prolyl cis-trans isomerase activity, CypA was initially thought to act as 
an uncoating factor [146]. In this model, CypA is proposed to interfere with CA-CA 
interactions thereby mediating the disassembly of the viral core within the cytosol of target 
cells after cell entry. However, the involvement of CypA in the uncoating process could not 
be confirmed by other studies [9, 149].  
 
A subsequent study demonstrated that CypA rather, acts prior to the uncoating step by 
mediating the initial attachment of HIV-1 to target cells [150]. This group, therefore proposed 
that HIV-1 attaches to target cells via an interaction between CypA and cell surface heparins 
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(fig. 1.6.1.2), as the first step. In a second step, once the envelope glycoprotein (gp120/gp41) 
is in close proximity to the plasma membrane, it then interacts with CD4 and chemokine 
receptors that trigger the fusion process. It is advantageous for HIV-1 to use a host protein, 
such as CypA, for viral attachment because it is a self-antigen. This may help HIV-1 escape 
a strong host immune response.  
 
Figure 1.6.1.2. Proposed model for the role of CypA in HIV-1 attachment. Host CypA is 
incorporated into nascent viruses via HIV-1 Gag. Viral maturation triggers the release of 
CypA from Gag, permitting the redistribution of CypA at the viral surface. By interacting with 
cell-surface heparans, exposed CypA mediates HIV-1 attachment to target cells. The initial 
CypA-mediated attachment permits the subsequent binding between HIV-1 envelope 
glycoproteins (gp120/gp41) and CD4 and chemokine receptors. This 
envelope/CD4/chemokine receptor complex triggers the fusion between viral and cellular 




This theory suggests that CypA interacts with heparans which are ubiquitously expressed on 
human cells. This observation was consistent with other studies that had already 
demonstrated that a number of viruses employ heparans for their initial step of infection [151-
156]. 
 
1.6.1.3 The role of CypA in HIV-1 replication in vivo 
Although a consensus has not been reached in terms of at what step of HIV-1 replication 
does CypA act, it is very clear that CypA promotes HIV-1 replication in vitro. The in vitro data 
demonstrated that HIV-1 replication was inhibited in CypA-null human CD4+ T cells (PPIA-/- 
Jurkat cells) [145]. This data demonstrated that CypA is an important cellular cofactor that 
promotes HIV-1 replication. 
 
Host genetic studies demonstrated an association between a PPIA polymorphism and HIV-1 
disease outcome [61, 73, 74], thereby validating the in vitro data. Bleiber et al. demonstrated 
that the minor variant (G) of the SNP A1650G (1650G), in the PPIA promoter region, was 
associated with higher ex vivo virus replication and rapid disease progression in a Swiss 
Caucasian HIV-1 cohort [61]. In the subsequent study [73], the 1650G was suggested to be 
associated with increased susceptibility to HIV-1 infection since it was found to be more 
frequent among HIV-1 positive individuals (the seroconverters (SC)) compared to high-risk 
exposed uninfected (HREU) cohort. However, the group did not find significant association 
between the 1650G and disease progression both in the European Americans (EA) and 
African Americans (AA). Interestingly, they found the minor allele (G) of SNP C1604G 
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(1604G) which is also in the promoter region of the PPIA, to be significantly associated with 
rapid disease progression both in EA and AA. The latest study on the role of the A1650G and 
C1604G SNPs upon exposure to HIV-1 infection [74], demonstrated that the frequency of the 
1650G was significantly increased in HREU compared to seropositive (SP) group, suggesting 
that the 1650G may be associated with reduced susceptibility to HIV-1 infection in 
participants of the Amsterdam Cohort studies (ACS). Lastly, Rits et al. found that the 1604G 
was significantly associated with reduced levels of CypA mRNA expression suggesting that 
the 1604G may down regulate the expression levels of CypA mRNA [74]. The association of 
the genetic variation in the PPIA with susceptibility to HIV-1 infection remains inconclusive as 
previous studies found contradictory results [73, 74], which could possibly be attributed to the 
fact that these studies used populations of different origins. Secondly, the influence of the 
PPIA polymorphisms on HIV-1 clinical outcomes in populations that bear the heaviest burden 
of HIV infection has not been studied. Therefore, this study investigated the association of 
genetic variation in the PPIA with HIV-1 clinical outcomes in South African HIV-1 study 
cohorts. 
 
1.6.2 The role of Transportin SR-2 in HIV-1 replication 
Transportin-SR2 (TRN-SR2), also known as transportin 3 (TNO3) is a cellular protein that 
shuttles essential splicing factors–such as serine/arginine-rich proteins–into the nucleus [157, 
158]. By convention, the gene and its protein are referred to as TNPO3 and TRN-SR2, 
respectively [126]. TRN-SR2 has been shown to play a pivotal role in HIV-1 replication [32, 




TRN-SR2 was initially identified as a host factor required by HIV-1 for infection [67, 68]. 
Subsequently,TRN-SR2 was identified as an HIV-1 IN binding protein and shown to mediate 
HIV-1 nuclear import [160]. Knockdown of the TNPO3 yielded significant inhibition of HIV-1 
replication indicating that TRN-SR2 is an important HIV-1 replication co-factor [67, 68, 160]. 
Interestingly, the block to HIV-1 infection was pinpointed at HIV-1 nuclear import, which 
suggested the role of TRN-SR2 in nuclear import [160]. However, Krishman et al. could not 
confirm the role of TRN-SR2 in HIV-1 nuclear import [32]. This study showed that TRN-SR2 
interacts with CA, instead of IN but these results have not been replicated. The most recent 
study demonstrated that depletion of TRN-SR2 altered the selection of integration sites on 
the chromosome [161]. Although the exact mode of action for TRN-SR2 in HIV-1 replication 
cycle is misunderstood, taken together these studies clearly demonstrate that TRN-SR2 is an 
important HIV-1 replication co-factor. 
 
Studies on the role of TRN-SR2 on HIV-1 replication have been done in vitro, meaning that 
these findings need to be confirmed in vivo. At the time of this PhD project, there was no in 
vivo data published on the role that TRN-SR2 may play upon HIV-1 exposure or infection. 
This project undertook to identify genetic variants in the TNPO3 gene that may be associated 
with clinical outcomes upon HIV-1 exposure. 
 
1.6.3 Host factors enhancing HIV-1 integration 
Purified pre-integration complexes (PICs) from infected cells preferentially integrate viral 
DNA into a target cell DNA intermolecularly thereby avoiding suicidal intramolecular 
autointegration [162]. Secondly they insert both viral DNA ends into a target cell DNA 
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efficiently, in a concerted manner [162, 163]. Although purified recombinant IN is sufficient to 
perform 3‟ processing and strand transfer reactions in vitro, it can only insert a single viral 
DNA end in a single strand of the duplex target DNA [164, 165].  
 
HIV-1 PICs are constituted by viral cDNA, proteins and cellular proteins. Therefore, results 
obtained from in vitro reactions using purified PICs would closely resemble the in vivo 
situation. High salt treated PICs are defective for integration and their activity can be restored 
upon addition of host cell cytoplasmic extracts [166]. This suggests that the presence of 
cellular factors in the PIC aids retroviral DNA integration. Amongst the cellular proteins 
reported to play a role in the HIV-1 integration process are Barrier-to-autointegration factor 
(BAF), High mobility group chromosomal protein A1 (HMGA1), Integrase interactor 1 (INI1) 
and Lens epithelium derived growth factor p75 (LEDGF/p75).  
 
BAF forms part of the PIC and directs the integration of viral cDNA into the target DNA, 
thereby preventing suicidal autointegration [165, 167]. HMGA1 restores the PIC activity after 
salt-stripping [134, 136]. However, there is no evidence for the requirement of HMGA1 in 
retroviral integration in vivo [166, 168]. Integrase interaction protein 1 (INI1) interacts with 
HIV-1 IN to enhance its strand transfer reaction [169] and has been shown to be important 
for HIV-1 replication [170]. LEDGF/p75 is a recently identified binding partner of HIV-1 [171] 





1.6.3.1 Lens epithelium derived growth factor p75 (LEDGF/p75) 
LEDGF/p75 is a member of the hepatoma-derived growth factor (HDGF) family. LEDGF/p75 
was first identified as a binding partner of the transcriptional co-activator C4, suggesting its 
role in transcriptional regulation [172]. This protein derived its name „lens epithelium derived 
growth factor‟ from its ability to stimulate and prolong cell survival of lens epithelium cells, 
cos7 cells, skin fibroblasts and keratinocytes when added to the culture medium [173]. 
 
LEDGF/p75 is a survival factor that is involved in promoting mammalian cell growth and 
protecting cells against stress-induced cell death [174]. LEDGF/p75 provides protection by 
transcriptionally activating stress-related or anti-apoptotic proteins [175] and is a DNA-
binding protein [176]. In addition to its cellular functions, LEDGF/p75 has been identified as 
the binding partner for HIV-1 IN [171]. This interaction was mapped to the C-terminal domain 
of LEDGF/p75 [177].  
 
LEDGF/p75 is 530 amino acids long (fig. 1.6.3.1.1). The N-terminal region of LEDGFp75 
contains a PWWP (for Pro-Trp-Trp-Pro) domain that is responsible for protein–protein 
interaction and DNA-binding [178, 179]. The C-terminal region of LEDGF/p75 contains an 
evolutionary conserved integrase binding domain (IBD) that interacts with HIV-1 IN [180]. 
LEDGF/p75 also contains a functional nuclear localization signal (NLS) [181, 182]. It is 
important to note that LEDGF/p75 has a splice variant, LEDGF/p52 (p52), which shares a 
region of 325 residues of the N-terminus but lacks the C-terminus of LEDGF/p75 [183]. 






Figure 1.6.3.1.1. Domain structure of LEDGF/p75 [184]. The different domains of p75 and 
p52 splice variants are highlighted. 
 
The IBD is a compact right-handed bundle composed of 5 α helices as was resolved by 
nuclear magnetic resonance and the amino acids Ile365, Asp366 and Phe406 were shown to 
be important for the interaction with HIV-1 IN [185]. In addition, this group reported a crystal 
structure of the dimeric catalytic core domain of HIV-1 IN complexed to the IBD [186]. 
  
The precise stoichiometry of the HIV-1 IN–LEDGF/p75 complex in the infected cell has not 
been elucidated and it suggests a symmetrical complex containing a pair of integrase 
tetramers and two subunits of LEDGF/p75 [156] (fig. 1.6.3.1.2). The nuclear distribution of 




Figure 1.6.3.1.2. Tethering function of LEDGF/p75 in analogy with yeast LTR 
retrotransposons [184]. (a) Ty3 integrates within one or two nucleotides of polymerase III (pol 
III) transcription initiation sites, probably by interaction with the transcription factors TFIIIB 
and TFIIIC. Ty5 integrates into heterochromatic DNA of telomeres and silent mating loci 
(HML and HMR) by interaction with the C-terminal portion of Sir4p. (b) Interaction of lentiviral 
integrase with LEDGF/p75 targets integration into transcriptionally active regions. 
 
Knock-down of endogenous LEDGF/p75 using small interfering RNA (siRNA) completely 
abolished the nuclear localization of HIV-1 IN and its association with chromosomes in cells 
[187], suggesting its involvement in HIV-1 nuclear import [188].  
 
1.6.3.2 Role of LEDGF/p75 during lentiviral integration 
It is clear from the data presented above that LEDGF/p75 is important for efficient HIV-1 
replication. Now the next step was to elucidate the exact function of LEDGF/p75 in the HIV-1 
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replication life cycle. In direct nuclear-import assays, recombinant HIV-1 IN was still actively 
imported into the nucleus in the absence of LEDGF/p75 [177]. Surprisingly, mutant HIV-1 IN 
(Q168A) defective for interaction with LEDGF/p75 failed to associate with the mitotic 
chromosomes. Moreover, these mutant viruses (Q168A) yielded normal levels of 2-LTR 
circles but failed to integrate. The results obtained from this study suggested that LEDGF/p75 
may not be a dominant factor for HIV-1 nuclear import but might be involved in the integration 
step of HIV-1 replication cycle.  
 
Subsequently, LEDGF/p75 was found to stimulate the binding of HIV-1 IN to the 
chromosomal DNA [189]. These results suggested that LEDGF/p75 could be functioning as a 
tethering factor of HIV-1 IN to the chromosomes. This plausible function explained the 
nuclear accumulation of HIV-1 IN and its association with mitotic chromosomes, both of 
which were abolished by knock-down of LEDGF/p75 [177, 188, 190, 191].  
 
HIV-1 is preferentially integrated into transcriptionally active regions, which allows efficient 
viral gene expression after integration [192]. Therefore, a plausible hypothesis at this time 
was that LEDGF/p75 played a role in the tethering of IN to the chromosomal DNA and 
targeting its integration to actively transcribed regions. LEDGF/p75-mediated site selection is 
reminiscent of target-site selection by yeast LTR transposons Ty3 and Ty5, which interact 




1.6.3.3 The role of LEDGF/p75 in lentiviral integration targeting 
Knockdowns of LEDGF/p75 showed a reduced integration frequency of HIV-1 within 
transcription units and an increase in the G/C content around sites of HIV-1 integration [195]. 
These data confirmed that LEDGF/p75 tethers HIV-1 to the chromatin and directs integration 
into active genes (fig. 1.6.3.3). In support of the tethering model, artificial fusion proteins in 
which the LEDGF/p75 IBD was fused to the sequence specific for DNA binding domain of 
phage lambda repressor favoured integration near repressor binding sites in vitro [196]. HIV-
1 binds to the IBD which is in the C-terminal then the PWWP domain which is in the N-
terminal region of LEDGF/p75 tethers HIV-1 to the host chromosome thereby promoting HIV-
1 replication [197]. This suggests that LEDGF/p75 needs both ends of LEDGF/p75 to 
promote HIV-1 replication. 
 
However, key questions still remain on the role of LEDGF/p75. In all the models studied, HIV 
continued to favor integration within active transcription units. This could either be because 
residual LEDGF/p75 remaining in the knockdown was sufficient for residual targeting activity, 





Figure 1.6.3.3. LEDGF/p75 and nuclear entry of PICs. LEDGF/p75 might regulate HIV-1 
replication through the tethering the IN to the chromatin and targeting integration into active 
genes [198]. NPC nuclear pore complex; PIC pre-integration complex. 
 
In an effort to address this issue, Shun et al. prepared a mouse strain that had part of the 
LEDGF/p75 locus flanked by Cre recombination sites [199], and the LEDGF/p75 exon 
regions deleted by exposure to Cre recombinase. Mouse embryonic fibroblasts were then 
studied for effects on infection with HIV-1 reporter viruses. These cells showed a 20-fold 
reduction in infectivity by HIV-1, and also a reduction in integration frequency in transcription 
units [195]. In addition, these mouse cells showed some new targeting features in the 




The role of LEDGF/p75 in tethering the IN to the host chromosome and targeting integration 
in transcription units was confirmed in human SupT1 T-cell line with intensified RNAi 
knockdown of LEDGF/p75 [197]. The mouse cells containing homozygous gene trap 
mutations at the LEDGF/p75 locus also confirmed the tethering effect of LEDGF/p75 [200]. 
Taken together these data demonstrated that LEDGF/p75 is a determinant of integration 
target site selection for HIV-1 and other lentiviruses in primary cells where LEDGF/p75 levels 
were not artificially reduced. 
 
1.6.3.4 Retargeting lentiviral integration into heterochromatin using LEDGF constructs 
Overexpression of the C-terminal fragment of LEDGF/p75 (amino acid 325–530; 
LEDGF325–530) or IBD alone did not only fail to mediate chromatin binding but also it 
relocated HIV-1-IN to the cytoplasm and blocked HIV-1 replication [201, 202]. The 
mechanism of chromatin association is believed to be facilitated by elements located in the 
N-terminal portion of LEDGF/p75. These include a PWWP domain, which contains a Pro-Trp-
Trp-Pro signature, a NLS and two AT hooks [197, 203] (fig. 1.6.3.4). It appeared that PWWP 
domain of LEDGF/p75 was responsible for chromatin binding and integration targeting and 
therefore Lin et al. constructed fusions of IBD and the λ repressor DNA–binding domain to 
test this. Interestingly, this fusion protein showed increased in vitro strand transfer activity 
near λ repressor–binding sites [166], implying that indeed PWWP is responsible for tethering 






Figure 1.6.3.4. Domain structure of LEDGF/p75 and schematic representation of 
LEDGF325–530 fusions. In the lower panel the DNA binding domain fusions with 
LEDGF325–530 are depicted, H1-LEDGF325–530, and CBX1-LEDGF325–530, respectively. 
Numbers indicate amino acids of each domain [204]. 
 
Fusion of the IBD and alternative chromatin-binding proteins retargeted lentiviral integration 
to alternative regions of the genome, when it was expressed in LEDGF/p75-depleted cells 
[204]. These findings further confirmed that the PWWP domain of LEDGF/p75 is responsible 
for integration targeting. Gijsberset al. developed fusion proteins (hybrids) between the IBD 
and different chromatin-binding proteins, with particular focus on domains with binding 




A fusion protein where the PWWP domain of LEDGF/p75 was replaced with CBX1 rescued 
the infection block in LEDGF/p75-depleted cells but the integration was retargeted to 
genomic sites bound by CBX1 [204]. Normally, these regions are disfavoured for lentiviral 
integration because their expression levels are very low. Interestingly, transgene expression 
from the vector was nevertheless efficient. These findings open possibilities of using gene 
therapy vectors to retarget IN integration to gene-poor regions thereby inhibiting HIV-1 
replication [204]. 
 
1.6.3.5 Small-molecule inhibitors (SMI) of the LEDGF/p75-integrase interaction and HIV 
replication 
The data presented above support the theory that LEDGF/p75 tethers the HIV-1 
preintegration complex (PIC) to cellular chromatin. Analysis of integration sites in human 
cells depleted for LEDGF/p75 by RNAi or in embryonic fibroblasts derived from LEDGF/p75 
knockout mice, corroborated the role of LEDGF/p75 as tethering and integration targeting 
factor of HIV-1 [195, 205]. 
 
Since LEDGF/p75-IN interaction has been shown to be important for efficient and productive 
HIV-1 infection, this interaction could be explored as a potential antiviral target. 
Overexpression of the C-terminal fragment (Δ325) of LEDGF/p75 in human cells resulted in 
the inhibition of HIV-1 replication [201]. In this study, the Δ325 containing no PWWP domain 
outcompeted the endogenous LEDGF/p75 for binding to the IN and this inhibited HIV-1 
replication to nearly undetectable levels (fig. 1.6.3.5). HIV-1 inhibition was due to the fact that 
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the Δ325 did not contain the PWWP domain and as a result was unable to tether HIV-1 to the 
host chromosome thereby inhibiting HIV-1 replication. 
 
 
Figure 1.6.3.5. Overexpression of the C-terminal domain of LEDGF/p75 (Δ325) outcompetes 
the endogenous LEDGF/p75 for binding to HIV-1 IN thereby inhibiting HIV-1 replication 
because it lacks (PWWP) chromatin binding domain [206]. 
 
Another study repeatedly passaged HIV-1 in cells overexpressing this Δ325, thereby causing 
HIV-1 to develop resistance against this phenotype [202]. Notably, two IN mutations (A128T 
and E170G) that are crucial for IBD-IN interaction, rendered IN resistant [207]. Subsequently, 
Christ et al. embarked on a rational drug design program to discover LEDGINs, small 
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molecule inhibitors that targeted the LEDGF/p75-IN interaction in order to inhibit HIV 
replication [208]. 
 
Protein-protein interactions (PPIs) between HIV-1 and host proteins (replication cofactors) 
constitute a pool of potential new antiviral targets against which small-molecule protein-
protein interaction inhibitors (SMPPIIs) can be designed. A new class of antiviral agents that 
effectively target the LEDGF/p75-IN interaction has been designed and synthesized, not only 
demonstrating the feasibility of exploiting PPIs as targets for drug discovery but also 
validating a new paradigm in anti-HIV research [208]. 
 
Christ et al. found 2-(quinolin-3-yl) acetic acid derivatives that blocked integration by 
inhibiting LEDGF/p75-IN interaction [209]. The 2-(quinolin-3-yl) acetic acid derivatives also 
moderately inhibited the enzymatic activity of HIV-1 IN. This did not come as a surprise since 
it is well known that LEDGF/p75 by itself act as an allosteric activator of IN activity. Although 
all compounds tested were more active on the cofactor binding than on the enzymatic 
activity, this allosteric function might add to the potent antiviral profile of this compound class. 
 
1.7 Conclusion 
AIDS has had a devastating effect on human health killing more 25 million people since its 
description in 1981 while there are about 33.4 million people living with HIV-1 worldwide 
(http://www.unaids.org).Despite the enormous efforts in developing new effective antiviral 
agents and the introduction of highly active antiretroviral therapy (HAART), the problem of 
HIV-1 infections persists. Although HAART is effective in chronically suppressing HIV-1 
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replication, antiretroviral treatment has been accompanied by development of resistance and 
toxicity in some patients. Therefore, the quest for developing new and safe antiviral agents to 
complement existing treatment strategies remains one of the main goals in HIV-1 drug 
discovery. Current antiviral drugs target the viral enzymes RT, PR and IN. For example, 
raltegravir (MK-518) targets the strand-transfer reaction of viral IN and inhibits the integration 
process thereby reducing viral replication [210, 211]. However, raltegravir resistance evolves 
readily in the clinic [212], necessitating the efforts to develop second-generation integrase 
inhibitors with beneficial resistance profiles.  
 
HIV-1 relies on replication cofactors for completion of its replication cycle and productive 
infection. Therefore, the second generation of HIV-1 inhibitors should target the interaction 
between viral and cellular proteins. Disruption of the interaction between HIV-1 and cellular 
proteins could potentially reduce viral resistance and block HIV-1 replication. 
 
HIV-1 replication cofactors are increasingly being targeted for antiretroviral therapy yet there 
are three fundamental challenges facing this approach: (1) there is very little information on 
genetic variation in the replication cofactors in humans and its impact if any upon HIV-1 
exposure; (2) studies on human genetic factors that affect HIV/AIDS pathogenesis have 
focused mainly on host immune factors and the failure of vaccines and immunotherapies in 
HIV-1 and; (3) host genetic studies have been conducted using populations from developed 
countries and of European origin yet genetic milieu of populations differ according to 




These challenges necessitate the need to explore other biomedical interventions that may be 
pursued for therapeutic and prophylaxis intervention using populations from developing 
countries, heavily burdened by HIV-1 epidemic. The current study addresses the latter 
challenge by studying the influence of genetic variation in select HIV-1 replication cofactors–
CypA, TRN-SR2 and LEDGF/p75–on susceptibility to HIV-1 infection and disease 
progression using a South African population. This study seeks to shift the focus from 
immune factors and look at genetic variation among South Africans who bear the greatest 
burden of infection as opposed to previous studies on mainly Caucasians or African 
Americans who may have a relatively low HIV/AIDS burden and different genetic milieu for 













2.1 Molecular Methods 
Understanding the patterns of single nucleotide polymorphisms (SNPs) is essential for the 
studies of the disease [213-216], in preventive medicine [217, 218], personalized medicine 
[219], forensics [220] and evolution [221]. Therefore, many SNP genotyping methods have 
been developed [222-224]. However, in this thesis we are discussing only three genotyping 
methods: (1) DNA sequencing; (2) polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) analysis and; (3) Taqman probe assay. In addition to genotyping 
methods, this thesis gives an overview of the AlphaScreen Assays since these techniques 
were used in this project to investigate genetic variation in relation to HIV pathogenesis and 
to measure protein-protein interactions. 
 
2.2 DNA Sequencing 
The introduction of polymerase chain reaction (PCR) advanced genetic research, leading to 
improved and faster DNA sequence analysis (DNA sequencing) and identification of different 
genes based on their DNA sequences. Two DNA sequencing techniques, Sanger (or 
dideoxy) method [225] and Maxam-Gilbert (chemical cleavage) method [226], had been 
developed in the late 1970‟s. The Sanger method is technically easier to apply, and, with the 
advent of PCR and automation of the technique, is easily applied to long strands of DNA 
including some entire genes. This technique is based on chain termination by dideoxy 
nucleotides during PCR elongation reactions.  
 
The Maxam-Gilbert method is based on nucleotide-specific cleavage by chemicals and is 
best used to sequence oligonucleotides, usually smaller than 50 base-pairs in length. Gel 
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electrophoresis technique with the ability to separate DNA fragments that differ in size by as 
little as one base pair forms an integral part of DNA sequencing. The Sanger (or 
dideoxynucleotide chain termination) method was therefore the method of choice in this 
study, given its simplicity and applicability. 
 
2.2.1 Sanger Method (Dideoxynucleotide chain termination) 
The sequencing reaction of the Sanger method consists of DNA template, single 
oligonucleotide primer, deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs) [183]. 
The sequencing reaction proceeds in the following steps: (1) denaturation of the DNA 
template; (2) annealing of oligonucleotide primer to single stranded DNA template; (3) DNA 
polymerase then starts extending the primer by incorporating dNTPs until, if by any chance, a 
ddNTP is incorporated instead of dNTP. This is a "chain termination" event, because ddNTPs 
lack the 3‟ OH group to which the next dNTP of the growing DNA chain is added. Without the 
3‟ OH, no more nucleotides can be added, and DNA polymerase falls off [225] (fig. 2.2.1).  
 
Higher concentrations of the ddNTPs in the reaction generate shorter sequencing products 
that are closer to the oligonucleotide primer. Lower concentrations of ddNTPs, on the other 













Figure 2.2.1. A schematic representation of sequencing reaction. DNA strand is synthesized 
by formation of phosphodiester bonds. In this example of the “C reaction”, the chain is 
terminated by the use of dideoxycytidine triphosphate (ddCTP) in place of deoxycytidine 
triphosphate (dCTP) (www.appliedbiosystems.com; 11 October 2010). 
 
However, newly synthesized products are a mixture of lengths, depending on how long the 
chain was when a ddNTP was randomly incorporated. Since the newly synthesized DNA 
products are labeled (classically with 35S-dATP) then these products can be detected and 
distinguished from the template because template DNA is not labeled. 
 
Before the invention of automated sequencing machines, these products were denatured into 
single stranded DNA molecules and run on a polyacrylamide/urea gel. Unlike the agarose 
gel, polyacrylamide gels allow resolution of DNA molecules that differ in size by only one 
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nucleotide [227]. The gel would be then dried onto chromatography and exposed to X-ray 
film. The template DNA is distinguished from synthesized products by the fact that the 
template strand is not radioactively labeled and therefore, does not generate a band on the 
X-ray film but newly synthesized products which are labeled strands do generate bands (fig. 
2.2.1.1 A).  
 
The chain termination events, as aforementioned, produce DNA or sequencing products of 
different lengths which results in individual bands on a gel as demonstrated using the "G" 










Figure 2.2.1.1. Sequencing products of different lengths. A, Mixture of products of different 
lengths synthesized for the "G" reaction. Each newly synthesized strand at some point had a 
ddGTP incorporated instead of dGTP resulting in chain termination. B, Polyacrylamide gel 
showing sequencing products of different lengths. Chain terminations closest to the primer 
generate the smallest DNA molecules that migrate the longest distance down the gel and 
chain terminations further from the primer generate larger DNA molecules that remain nearer 
to the top. C, Chain termination reactions for all four nucleotides are run next to each other to 
read the sequence of the DNA off of the "ladder" from bottom to top. D, Large polyacrylamide 
gel allows DNA molecules to migrate further and be better resolved 





Different sizes of newly synthesized products (fragments) migrate different distances on a gel 
during gel electrophoresis which generate different banding patterns. The shortest (smallest 
DNA fragment) product migrates further down on the gel whereas the largest DNA molecule 
migrates slower on the gel during electrophoresis, remaining nearer to the top of the gel 
[228].  
 
The chain termination reactions could be performed for all four nucleotides (A, C, G and T) 
concurrently, and when these four reactions are run next to each other on a gel, then the 
sequence of the DNA could be read off of the "ladder" of bands, 5' to 3' sequence being read 
from bottom to top (fig. 2.2.1.1C) [229]. 
 
The resolution of the gel electrophoresis is very important in DNA sequencing. DNA 
molecules that are 50, 100, or 200 bases in length must be separable from the DNA 
molecules that are 51, 101, or 201 bases in length, respectively. Large polyacrylamide gels 
are therefore used to separate DNA molecules that differ in length by either one or a few 
nucleotides because these gels allow the molecules to migrate further and be better resolved 
(fig. 2.2.1.1D) [230]. Firstly, samples must be denatured before they are loaded onto the gel, 
and secondly these polyacrylamide gels should contain a high concentration of urea (7 to 8 
molar) to prevent folding of the molecules and formation of secondary structures by hydrogen 
(H) bonding that would alter the mobility of the molecule [231]. Formation of H bonds is 




Increased ddNTP:dNTP ratio results in more sequences closer to the primer making it 
difficult to read sequences of 200 to 300 nucleotides further down, since most of the synthetic 
products would have terminated earlier.  
 
2.2.2 Automated DNA sequencing: Dye termination sequencing 
The Sanger method chain termination reactions are still used, but pouring, running, and 
reading polyacrylamide gels have been replaced by automated methods. Instead of labeling 
the products of all 4 sequencing (chain termination) reactions the same, each ddNTP is 
labeled with a different fluorescent marker (fig. 2.2.2A).  
 
Figure 2.2.2. Automated DNA sequencing: Dye termination sequencing. A, ddNTP labeled 
with a different fluorescent marker, B, gel on the left shows chain termination reactions run 
individually and gel on the right shows four chain termination reactions that were performed 
in the same tube, and run on a single lane. C, chromatogram showing fluorescence intensity 




The laser beam of the automated DNA sequencing machine, excite four different kinds of 
products which get detected and the fluorescence intensity of these products is translated 
into a data “peak” [232]. 
 
Thus all four chain termination reactions can be performed in the same tube, and run on a 
single lane on a gel (fig. 2.2.2B). The sequencing machine scans the lane with a laser and 
the wavelength of fluorescence from the label conjugated to the ddNTPs can be interpreted 
by the sequencing machine as an indication of which reaction–ddG, ddA, ddT, or ddC–a 
particular DNA band came from. The fluorescence output is stored in the form of a 
chromatogram (fig. 2.2.2C). Although different automated DNA sequencing approaches exist, 
in this study we used the Applied Biosystems (ABI) (www.appliedbiosystems.com) approach 
to sequence DNA obtained from the participants of this study. This approach uses the ABI 
ready reaction mix to sequence the DNA. 
 
2.2.3 ABI PRISM™ Dye Terminator Cycle Sequencing Kits 
The ABI ready reaction mix used for sequencing (chain termination) reaction contains 
AmpliTaq® DNA polymerase, fluorescent sequencing (FS), labeled dye ddNTPs/primers, 
dNTPs, rTth pyrophoshatase, magnesium chloride and buffer. 
 
AmpliTaq® DNA Polymerase, FS is a mutant form of Thermus aquaticus (Taq) DNA 
polymerase and contains a point mutation in the active site of Taq DNA polymerase, 
replacing phenylalanine with tyrosine at residue 667 (F667Y) [233]. This point mutation 
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(F667Y) reduces discrimination against dideoxynucleotides and leads to a much more even 
peak intensity pattern [234]. The N-terminal domain of AmpliTaq® DNA Polymerase, FS 
possess a point mutation that results in glycine to aspartate change at residue 46 (G46D), 
which removes almost all of the 5´3´ nuclease activity. This eliminates artifacts that arise 
from the exonuclease activity. The enzyme has been formulated with a thermally stable 
inorganic pyrophosphatase that cleaves the inorganic pyrophosphate (Ppi) byproduct of the 
extension reaction and prevents its accumulation in the sequencing reaction.  
 
In the presence of high concentrations of Ppi the polymerization reaction can be reversed 
[235], a reaction called pyrophosphorolysis. In this reaction, a nucleoside monophosphate is 
removed from the extension product with the addition of Ppi to form the nucleoside 
triphosphate. In a sequencing reaction, if a dideoxynucleotide is frequently removed at a 
particular position and replaced by a deoxynucleotide, eventually there is little or no chain 
termination at that location. This would result in a weak or missing peak in the sequence data 
[236]. With dye terminator labeling, each of the four dideoxy terminators (ddNTPs) is tagged 
with a different fluorescent dye. The growing chain is simultaneously terminated and labeled 








Figure 2.2.3. One cycle of dye terminator cycle sequencing. Features of Dye-labeled 
Terminator Reactions: An unlabeled primer can be used. Dye terminator reactions are 
performed in a single tube. They require fewer pipetting steps than dye primer reactions. 
Four-color dye labeled reactions is loaded in a single gel lane or capillary injection. False 
stops, i.e., fragments that are not terminated by a dideoxynucleotide, go undetected because 
no dye is attached (www.biosystems.com, May 2011). 
 
Dye-labeled primer reactions produce more even signal intensities than dye terminator 
chemistries. Labeled primers are available for common priming sites and customer designed 
primers can also be labeled. Four-color dye-labeled reactions are loaded onto a single lane 























Figure 2.2.3.1. One cycle of dye primer cycle sequencing. Features of Dye-labeled Primer 
Reactions: Dye primer chemistries generally produce more even signal intensities than dye 
terminator chemistries. Labeled primers are available for common priming sites. Custom 
primers can also be labeled. Four-color dye-labeled reactions are loaded onto a single lane 
or capillary injection (www.biosytems, May 2011). 
 
Although either approach could be used, depending on the objectives of the experiment, dye-
terminator reactions approach has advantages over dye primer approach. These include: (1) 
use of unlabeled primer and performing reactions in a single tube; (2) fewer pipetting steps; 
and (3) false stops, that is, fragments that are not terminated by a dideoxynucleotide go 





2.2.4 Sequencing Chemistry 
During the development of a new sequencing chemistry, alternative dye/base relationships 
were investigated to see which produces the most uniform signal in the analyzed data. For 
this reason, different sequencing chemistries may have different dye/base relationships. 
Three different sequencing chemistries were developed [237]: (1) Rhodamine dye 
terminators, which utilizes terminator dye label (A - R6G, C – ROX, G - R110, T – TAMRA); 
(2) dichloroRhodamine (dRhodamine) terminators, also utilizes terminator dye label (A - 
dichloro[R6G], C - dichloro[TAMRA], G -dichloro[R110],  T - dichloro[ROX]); and (3) 
BigDye™ terminators, which uses the terminator acceptor dye (A - dichloro[R6G], C - 
dichloro[ROX], G - dichloro[R110], T - dichloro[TAMRA]).  
 
In this PhD project we used BigDyeTM terminator sequencing chemistry because of the 
following reasons: BigDyeTM terminator chemistry is: (1) 2–3 times brighter than the 
rhodamine dye terminators; (2) have a narrower emission spectra than the rhodamine dye 
terminators, giving less spectral overlap and therefore less noise; and (3) has the brighter 
signal and decreased noise which provide an overall 4–5X gain in signal-to-noise ratio [238]. 
In addition, the dNTP mix used in BigDyeTM terminator sequencing chemistry includes dITP 
in place of dGTP to minimise band compressions. The dNTP mix also uses dUTP in place of 
dTTP and the dUTP is known to improve the incorporation of the T terminator resulting in a 
better T pattern. Applied Biosystems BigDyeTM terminator cycle sequencing chemistry 
provides a comprehensive solution for today‟s wide range of sequencing applications. For 
applications at every throughput level, these robust chemistries give longer reads and the 
58 
 
highest data quality ever. They successfully read through challenging motifs and challenging 
templates. 
 
2.2.5 Genetic Analyzers 
Sequencing machines referred to as genetic analyzers are used to analyze fluorescently 
labeled DNA fragments generated by sequencing reactions. While there are different series 
of genetic analyzers, this section briefly discusses 3100 series of the genetic analyzers 
focusing particularly on the ABITM 3130XL genetic analyzer since it was used in this PhD 
project.  
 
ABI 3100 series use virtual filter sets to detect light intensity in four non-overlapping regions 
on a CCD camera [239]. Each region corresponds to a wavelength range that contains or is 
close to the emission maximum of an ABI PRISM dye used in the sequencing reaction. This 
process is similar to using a physical filter to separate light of different wavelengths, however, 
the instruments do not use physical filtering hardware hence they are called virtual filters. 
The intensity display from the four light-collection regions is color coded by data collection 
software to appear as the blue, green, black (yellow on gel images), and red peaks in the raw 
data. The software always displays analyzed data with A as green, C as blue, G as black, 
and T as red in the electropherogram view.  
 
The ABI 3130XL Genetic Analyzer is a 16-capillary, fluorescence-based capillary 
electrophoresis system [240]. In addition to being a DNA sequencer it can run a wide variety 
of sequencing and fragment analysis applications including microsatellite analysis, amplified 
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fragment length polymorphisms (AFLP), loss of heterozygosity (LOH), SNP validation, and 
SNP screening. ABI 3130XL Genetic Analyzer can perform de novo sequencing and 
resequencing (mutational profiling). This system incorporates an automated polymer delivery 
process. This eliminates the need for manual filling, priming and loading of polymer, reducing 
time and decreasing run to run variation. This versatile platform delivers performance with 
higher data quality, improved automation and ease-of-use, faster turnaround times and 
higher reliability across the complete range of sequencing, resequencing, and fragment 
analysis applications. The full range of applications can be run on a single polymer and 
capillary array meaning applications could be mixed on one plate (www.appliedbiosystems, 
August 2010). 
 
The ABI 3130XL Genetic Analyzer has DNA Sequencing Analysis Software v5.1 integrated 
into it. This software is designed to analyze, display, edit, save and print sample files 
generated from ABI 3130XL Genetic Analyzer. The software contains a novel basecaller 
algorithm that performs base calling for pure and mixed base calls, it generates quality 
values to provide basecall accuracy information for pure and mixed base calls. This software 







2.3. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-
RFLP) 
Single nucleotide polymorphisms (SNPs) usually occur once every several hundred base 
pairs [241]. The ability to accurately determine the DNA sequence at specific sites throughout 
the individual‟s genome is important for a number of applications including disease detection, 
personalized medication, etc. (see section 2.1). The human genome project reported over 10 
million SNPs that occur in the human genome (www.ornl.gov). A number of rapid and reliable 
methods or techniques have been developed to analyze DNA for the purpose of detecting 
DNA variation or SNPs.  
 
2.3.1. Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) is a technique that allows production of large quantities of 
a specific DNA sequence in a simple enzymatic reaction in vitro [242, 243]. PCR has 
transformed the way that almost all studies requiring the manipulation of DNA fragments may 
be performed as a result of its simplicity, usefulness and cost effectiveness [244]. PCR 
generates large quantities of a target sequence which are enough for downstream analysis. 
Unique oligonucleotide primers complimentary to the ends of the target sequence to be 
amplified need to be designed. These primers and the DNA template containing the target 
sequence are mixed with commercially available PCR reagents: PCR buffer; magnesium 
chloride (Mgcl2); dNTPs; enzyme (DNA polymerase); and appropriate buffer. This reaction 
mixture is then subjected to repeated cycles of denaturation of the original strands of DNA, 
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primer annealing to the opposite ends of the denatured target DNA, and extension of primers 








Figure 2.3.1. Target DNA (represented in red) amplification by PCR. The amount of target 
DNA produced by PCR doubles every cycle.  
 
The newly synthesized strand will overlap the binding site of the opposite oligonucleotide 
primer. Large quantities of target DNA get produced as repeated cycles of PCR continue (fig. 
2.3.1). The end result is an exponential increase in the total number of DNA copies of the 
targeted sequence, which are finally represented as a theoretical abundance of 2n where “n” 





2.3.2 Restriction Fragment Length Polymorphism (RFLP) 
Restriction fragment length polymorphism (RFLP) is a technique used for detection of 
polymorphisms that result in the loss or creation of a recognition site for a restriction 
enzymes to cleave the DNA [247]. Restriction enzymes recognize the restriction sites on the 
DNA molecule and cleave the DNA molecule at these sites to generate DNA molecules of 
varying length, which are called RFLP. DNA molecules are negatively charged at neutral pH 
due to their phosphate backbone and therefore migrate towards the cathode when subjected 
to an electric potential (fig. 2.3.2 A) [248]. In most cases somatic mutations in disease-related 
genes do not give rise to a functional change of the mutated cell which would allow its 
isolation or expansion in vitro. Therefore, selection of mutated cells on the basis of an altered 
phenotype has to be replaced by biochemical separation and detection of the altered 
sequence of the gene of interest.  
 
Evidently such 'genotypic' mutation analysis requires large numbers of cells at the outset 
since the expansion of mutated cells is avoided. To overcome this hurdle RFLP technique 
was combined with polymerase chain reaction (PCR) to develop a new technique called 
polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) [222]. 
PCR amplifies the target DNA sequence to large quantities and the PCR product is 













Figure 2.3.2. A, schematic diagram showing DNA migration when subjected to an electric 
field; B, separation of DNA fragments by agarose gel electrophoresis following restriction 
digestion. 
 
The generated fragments are separated to their respective sizes accordingly by gel 
electrophoresis. The restriction enzymes recognize specific short palindromic sequence of 
four to eight nucleotides and hydrolyze the phosphodiester backbone of both DNA strands at 
these specific recognition sites [247].  
 
Although a SNP in the restriction site or genetic code does not necessarily affect the function 
of the gene, these SNPs may alter the recognition site of enzymes used for PCR-RFLP 
analysis. Polymorphism occurring at the restriction site gives rise to banding patterns of DNA 
restriction fragments. Fragments of the digested DNA are separated by agarose gel 
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electrophoresis to resolve the banding patterns and measure the size of restriction fragments 
(fig. 2.3.2B). DNA molecules (or restriction fragments) sieve through the pores of agarose gel 
matrix at different rates, determined largely by their mass because the charge to mass ratio 
of all molecules is uniform [249]. The smaller DNA molecules migrate the furthest distance 
down the gel with the larger molecules remaining closest to the well after electrophoresis. 
 
If several samples have been loaded into adjacent wells of the gel, they run parallel in 
individual lanes. Depending on the number of different fragment sizes, each lane shows 
different bands on the gel which correspond to each fragment size. Incomplete separation of 
the fragments leads to overlapping bands, or to indistinguishable smears representing 
multiple unresolved DNA fragments [250]. 
 
2.4. TaqMan® SNP Genotyping Assays 
TaqMan® SNP Genotyping Assay is a single-tube PCR assay that exploits the 5‟ 
exonuclease activity of AmpliTaq Gold® DNA Polymerase [251, 252]. The assay includes two 
locus-specific PCR primers that flank the SNP of interest, and two allele-specific 
oligonucleotide TaqMan® probes. These probes have a fluorescent reporter dye at the 5‟ 





An intact probe emits minimal fluorescent signal when excited because 5‟ fluorophore is in 
close physical proximity with the 3‟ quencher and this causes the fluorescent resonance 
energy transfer (FRET) effect to quench the fluorescence emitted by the fluorophore [209]. A 
strong fluorescent signal is generated when the intact probe hybridized to the target allele, is 
cleaved by the 5‟ exonuclease activity of AmpliTaq Gold® DNA Polymerase. The PCR 
primers amplify a specific locus containing the SNP of interest and each fluorescent dye-
labeled hybridization probe reports the presence of its associated allele in the DNA sample 
(fig. 2.4) [254, 255].  
 
Figure 2.4. TaqMan reaction (www.appliedbiosystems.com, May 2011). 
 
In each PCR cycle, cleavage of one or both allele-specific probes produces an exponentially 
increasing fluorescent signal by freeing the 5‟ fluorophore from the 3‟ quencher. The use of 
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two probes, one specific to each allele of the SNP and labeled with two fluorophores, allows 
detection of both alleles in a single tube.  
 
Fluorogenic probes with an MGB produce enhanced allelic discrimination, because the MGB 
stabilizes the double stranded probe-template complex, thereby increasing the probe melting 
temperature without increasing probe length [256]. This provides enhanced mismatch 
discrimination between these shorter probes, resulting in improved allele specificity. These 
probes also increase the signal-to-noise ratio of an assay, because the reduced distance 
between the 5‟ fluorophore and the 3‟ quencher provides more efficient quenching of an 
intact probe [255]. 
 
2.4.1 TaqMan Assay Design 
ABI has predesigned TaqMan SNP assays for almost all the SNPs that were discovered from 
the human genome project; these assays are commercially available and are ready to use 
(www.appliedbiosystems.com). However, newly described SNPs and few other SNPs 
existing in the SNP database (www.ncbi.nlm.nih.gov/SNP) would not have predesigned 
TaqMan SNP assays. For these SNPs, ABI developed a proprietary algorithm that allows 
researchers to design TaqMan primers and probes for TaqMan SNP Genotyping Assays. 
This primer and probe design algorithm implements the thermodynamic and heuristic rules 
described in their TaqMan assay design guidelines [253], as well as additional empirically 




To increase the probability of generating a successful assay design, it is important first to 
mask all known SNPs and other polymorphisms within the region of the target polymorphism 
(reviewed in [255]). The masking of known SNPs ensures that: (1) the design pipeline does 
not place an oligonucleotide primer or probe over a base that is masked; (2) primers and 
probes are designed to the most conserved regions between individuals; and (3) 
oligonucleotide primers hybridize efficiently to the target regions that flank the SNP of 
interest. 
 
2.4.2 Allele calling and visualization of results 
The TaqMan SNP Genotyping Assay is read at the endpoint of PCR rather than in real time. 
Genotyping is performed in 96- or 384-well plates that allow many DNA samples to be 







Figure 2.4.2.1. A, Cluster plot of 88 Coriell DNA samples and eight no-template controls 
(NTCs) from a typical TaqMan assay. B, Polar plot of same data. TaqMan assay data are not 
usually displayed in a polar plot (not available in the current commercially available software), 
but they are shown in this view to facilitate interpreting and comparing the SNPlex 
Genotyping System data [255] shown in the next figure. 
 
Individual alleles of a SNP are presented as a dot of the normalized intensity of the reporter 
dyes in each sample well on a cartesian plot, also known as a scatter or cluster plot. A 
clustering algorithm in the data analysis software assigns individual sample data to a 












Figure 2.4.2.2. An example of multi-cluster data produced by a target SNP, CYP2D6, a gene 
that has additional copies in some individuals [255]. 
 
SNP Genotyping Assays that produce more than the three clusters expected for bi allelic 
SNPs provide clues about biological differences in samples that behave anomalously. Extra 
clusters could be caused by the differences in DNA samples which include (1) unidentified or 
rare SNP that underlies a primer or probe, (2) the targeted SNP region having an additional 
copy (exon, gene, or genomic region) in the genome, and (3) the fact that a SNP of interest 
may contain more than two alleles [255]. These clues, exhibited as anomalous results in 





TaqMan SNP Genotyping Assays provide six significant technological advantages, which 
include the fact that these assays require only a single enzymatic step, use universal 
reactions and thermal cycling conditions. TaqMan SNP Genotyping Assays contain two 
specific primers targeting the region flanking the SNP site and two TaqMan fluorescent 
probes and can also genotype insertions/deletion polymorphisms in addition to SNPs [257]. 
The workflow is simple involving the adding of Universal Master Mix and the assay to the 
sample, followed by PCR and endpoint read [257]. The availability of a large number of 
validated, off the-shelf TaqMan SNP Genotyping Assays [257] makes it possible to 
implement a streamlined laboratory workflow. In addition, these assays require only simple, 
pre-PCR liquid-handling steps, which can be easily automated with a robotic liquid-handling 
process. 
 
2.5 Amplified Luminescent Proximity Homogeneous Assay Screen (AlphaScreen) 
The observation that, besides intrinsic enzymatic activities, proteins exert virtually all of their 
functions through interacting with other molecules such as nucleic acids, lipids, 
carbohydrates or small molecules and other proteins, has driven the development of 
technologies to examine these interactions [258]. The amplified luminescent proximity 
homogeneous assay screen (AlphaScreen) is an example of such technology developed to 
measure these interactions [259].  
 
This technology employs oxygen channeling chemistry developed from a diagnostic assay 
technology known as luminescent oxygen channeling immunoassay (LOCI) [260, 261]. LOCI 
cause the excitation of a cascading series of chemical reactions generating 
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chemiluminescent signal, a process referred to as chemical generation. This approach takes 
the advantage of the short diffusional distance of singlet oxygen to initiate a 
chemiluminescent reaction in the proximity of chemical generation. AlphaScreen is 
insensitive to interference by particles or other substances present in biological sample 
matrices [259].  
 
The assay format comprises two discrete ligand coated polystyrene beads, designated as 
“Donor” and “Acceptor” beads, which form pairs in the presence of analyte. The pairs must 
be within about 200 nm (approximately the diameter of a bead particle) in order for a 
chemiluminescent signal to be generated [259]. Donor beads contain a photosensitizing 
agent (phthalocyanine) that, when irradiated at 680 nm, excites ambient oxygen to a singlet 
state [260, 261]. Excitation of each Donor bead generates approximately 60,000 oxygen 
singlets per second [262], resulting in an amplified response when they come into contact 
with Acceptor beads. 
 
In an AlphaScreen assay, the Acceptor beads contain three chemical dyes namely, thioxene, 
anthracene and rubrene (hence the designation, „TAR‟ beads) [259]. Thioxene reacts initially 
with singlet oxygen to produce light energy, which is subsequently transferred to anthracene 
and thence to rubrene. The final compound in the cascade, rubrene, emits light at 
wavelengths of 520-620 nm [260]. This process occurs against a very dark background and 





Consequently, non-specific close proximity interactions of Donor and Acceptor particles is 
rare and again the background is low (fig. 2.5), which increase the sensitivity and specificity 
of this assay [259].  
  
 
Figure 2.5. The AlphaScreen assay is based on an oxygen channeling technology. When the 
Donor (blue bead) containing phthalocyanine is laser excited (at 680 nm) ambient oxygen is 
converted to singlet oxygen. Singlet oxygen molecules travel at least 200 nm in aqueous 
solution before decay. If the Donor and Acceptor (gold beads) beads are within that 
proximity, energy transfer occurs. Singlet oxygen molecules react with chemicals in the 
Acceptor beads to produce a luminescent response. If the Acceptor bead contains Europium 




The lifetime of the singlet oxygen reactive species in aqueous solutions is very short (approx. 
4 ms) therefore donor and acceptor beads rely on an immunological complex to be bound to 
one another in order to generate a signal. Unbound beads experience insignificantly low 
concentrations of singlet oxygen, contributing minimally to the background signal [259]. The 
AlphaScreen technique has been shown to be remarkably acquiescent for the detection of 
protein–DNA, protein–RNA, or protein–small molecule interactions, as well as protein–protein 
interactions [258]. In the current study, AlphaScreen was used to measure protein-protein 
interaction.  
 
2.5.1 Protein-Protein Interaction Assay Using AlphaScreen 
AlphaScreen was one of the technologies developed to measure protein-protein interactions 
that can be used to identify either small molecule inhibitors or novel interacting partners. The 
interaction of cells occurs through complex protein-protein interactions, ranging from ligand 
binding, G protein coupling reaction, interaction of kinases with cognate substrates as well as 
the interaction of transcription factors with nuclear co-activators and co-repressors [258]. 
 
Growth factor proteins such as tumor necrosis factor alpha (TNFα) receptors are implicated 
in the etiology of many inflammatory and immunological disorders. Therefore an 
AlphaScreen assay was developed to measure ligand binding to a member of the TNF 
receptor super-family, OX40 (CD 134) [263]. This group developed a fusion protein where 
OX40 was coupled to a domain of human IgG, allowing OX40 to bind to Acceptor beads 
coated with protein A and OX40 ligand (OX40L-CD8) tagged with biotin which was 
coordinated by streptavidin coated Donor beads [263]. This led to the identification of several 
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peptides and small molecules that inhibited OX40L binding. Human papilloma virus (HPV) 
protein E6 interacts with ubiquitin ligase, E6AP to inhibit the activity of a tumor suppressor 
protein (p53) and block transformed cells from undergoing apoptosis [264]. Since HPV 
causes cervical cancer by inhibiting the interaction between E6 and E6AP [265] then 
AlphaScreen assay was developed to measure E6 binding to E6AP. This assay was 
subsequently used to detect inhibitors of this interaction [266].  
 
The interaction between HIV-1 IN–LEDGF/p75 represents an attractive target for antiviral 
therapy. AlphaScreen assay has also been used to identify small-molecule inhibitors that 
target HIV-1 IN–LEDGF/p75 interaction [267]. Subsequently, Christ et al. rationally designed 
a series of 2-(quinolin-3-yl) acetic acid derivatives–LEDGINs–that act as potent inhibitors of 
the HIV-1 IN–LEDGF/p75 interaction [208]. This study demonstrated that LEDGINs inhibit 
HIV-1 replication by blocking the integration. The 2-(quinolin-3-yl) acetic acid derivatives 
could be defined as the first genuine allosteric HIV-1 integrase inhibitors because of their 
potent inhibition of HIV-1 replication and lack of cross resistance [208]. The data presented 
above indicate that the AlphaScreen technology provides a simplistic assay platform to 










3. Materials and Methods 
 
3.1 Study Participants 
The Center for the AIDS Programme of Research in South Africa Acute Infection 002 
(CAPRISA AI 002) [268, 269] and the Sinikithemba [84, 270, 271] cohorts were used for this 
study.  The CAPRISA AI 002 cohort is an ongoing observational natural history study of HIV-
1 subtype C infection established in Durban, KwaZulu-Natal, South Africa in 2004. HIV 
negative females (n=245) at high risk for HIV infection were enrolled into Phase I of the 
study. Participants in this cohort were screened monthly for recent HIV-1 infection by two 
rapid HIV-1 antibody tests (Abbott Laboratories, Tokyo, Japan) and Capillus (Trinity Biotech, 
Jamestown, NY, USA). HIV-1 antibody negative samples were tested for HIV-1 RNA in 
batches of 10 plasma samples per pool using the Ampliscreen v1.5 assay (Roche 
Diagnostics, Rotkreuz, Switzerland), which has a detection limit of 10 copies/ml. Samples 
that tested positive in pooled plasma were individually tested by quantitative RNA (Amplicor 
v2.0, Roche Diagnostics) and HIV enzyme immunoassay (BEP 2000; Dade Behring, 
Marburg, Germany) to identify HIV-1 infection. CD4+ T cell counts were determined by a 4-
parameter FACSCalibur flow cytometer (Becton Dickinson).  
 
 Participants with acute HIV-1 infection were enrolled into Phase II of the study on the basis 
of a reactive HIV antibody test within 3 months of previously negative results or positive HIV 
RNA PCR in the absence of antibodies. Date of infection was estimated by taking the 
midpoint between the last HIV antibody-negative result and the first HIV antibody-positive 
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result or 14 days before the first positive HIV RNA PCR assay result for those identified as 
antibody negative but HIV RNA positive. An additional of 34 acutely infected participants 
(who met the criteria for acute infection, as aforementioned) were recruited from other 
ongoing CAPRISA cohorts. Participants in Phase II were monitored weekly for 3 weeks, 
fortnightly for 2 months then monthly for 9 months and quarterly thereafter. 195 out of 217 
DNA samples obtained from participants who remained HIV-1 negative and 52 of the 62 DNA 
samples obtained from participants with acute HIV-1 infection were available for genotyping 
by TaqMan (fig. 3.1.1).  
                                                                                                                                       
 Figure 3.1.1. Description of CAPRISA AI 002 study cohort indicating the number of 




The Sinikithemba cohort comprises 450 antiretroviral naïve, HIV-1 subtype C chronically 
infected adults enrolled from McCord Hospital (Durban, South Africa) from August 2003 to 
2008 and followed longitudinally [84, 270, 271]. Sociodemographic characteristics, plasma 
viral load and CD4 cell count measurements were obtained at baseline. CD4 cell counts and 
viral loads were measured every 3 and 6 months respectively from enrollment. Viral loads 
were determined using the automated CobasAmplicor HIV-1 Monitor test (version 1.5; Roche 
Diagnostics). CD4+ T cells were enumerated using the Multitest kit (CD4/CD3/CD8/CD45) on 
a FACSCalibur flow cytometer (Becton Dickinson). 403 out of 450 DNA samples obtained 
from participants with chronic HIV-1 infection (Sinikithemba cohort) were available for 
genotyping by TaqMan assays (fig.3.1.2). 
 




Ethical approval for this study was obtained from Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal. All participants provided written informed consent. 
 
3.2 Molecular Analysis of DNA variation 
The DNA was extracted from the buffy coats obtained from the participants of this study 
using Qiagen DNA extraction kit according to the manufacturer‟s instruction 
(www.qiagen.com). The purity and quantity of DNA was measured by Nano Drop 2000/2000c 
spectrophotometer (Thermo Scientific). The DNA yield obtained using this kit was in the 
range of 100 ng/µl and the sample was considered pure if the A260/A280 reading was 1.8. 
 
3.2.1 Sequencing of the Integrase Binding Domain (IBD) of LEDGF/p75 
The IBD that interacts with HIV-1 IN is in the C-terminus region of LEDGF/p75. This study 
first screened part of the C-terminus region of PSIP1, which includes the IBD, for new 
polymorphisms by re-sequencing a DNA panel obtained from 83 HIV-1 seronegative 
participants (SN) and 43 HIV-1 seropositive participants (SP) from the CAPRISA AI 002 
cohort. A set of three sequencing primers (fig. 3.2.1) and ABI PRISMTM Dye terminator cycle 
sequencing core kit (Perkin Elmer, Brussels Belgium) was used in re-sequencing this panel 
of 126 DNA samples in a 3130 XL Genetic Analyzer (Applied Biosystems). 
 
Sequencing primers covered 1679bp long DNA fragment starting from 1190 bp up stream of 
exon 10 through to the end of exon 13 of the PSIP1 gene. Firstly, a 2664bp long fragment 
was amplified using two specific PCR primers: forward primer LEDGFDNA1 5‟-TGGGCTCAA 
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AGC ATTAATCC -3‟ and a reverse primer Seq5 5'- CTCTGAAGGATTCTACACTAGATAAC -
3‟. 
 
A 50µl PCR reaction containing 1X PCR buffer, 3.5 mmol/µl MgCl2, 0.25 mmol/µl dNTPs, 
0.25 U/µl Expand Taq (Roche), 0.4ρmol/µl of each primer (forward and reverse primer) and 
100ng DNA sample was prepared. This was amplified at 95 ºC for 10 minutes followed by 35 
cycles of 94 ºC for 30 seconds, 60 ºC for 30 seconds, 72 ºC for 45 seconds, and a final 10 
minute extension step at 72 ºC. The PCR products were purified using Qiagen PCR 
Purification Kit (Qiagen) according to manufacturer‟s instruction (www.qiagen.com). 
 
3.2.2 Genotyping for regulatory SNPs in the PPIA gene using PCR-RFLP  
DNA samples from 47 SPs and 168 SNs from the CAPRISA AI 002 cohort were available for 
genotyping by PCR-RFLP. For analysis of these polymorphisms in the promoter region of the 
PPIA, DNA samples were amplified by PCR using Taq DNA polymerase (Invitrogen) in the 
presence of 1.25 mmol/µl MgCl2, 0.4 mmol/µl dNTPs, and a primer pair CYPAex-1s (5‟-
AAGTCGCAGACCCGATTG-3‟) and CYPAex-1a (5‟-ACTTTCTGGGCCCCATTC-3‟) at 10 
ρmol/µl each. The following amplification cycles were used: 10 min 95 ºC; 35 cycles of 30 s 
94 ºC, 30 s 60 ºC, 45 s 72 ºC; 5 min 72 ºC.  
 
Subsequently, PCR products (250 bp in length) were subjected to a restriction digest with 
either RsaI or HAEIII (4 hours to overnight at 37oC; New England Biolabs) to detect 
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polymorphisms and analyzed by 4% agarose gel electrophoresis. RsaI restriction digestion 
was used to detect the SNP A1650G: a PCR product containing the wild type genotype (AA, 
referred to as 1650AA in this report) of the SNP A1650G resulted in 2 restriction fragments of 
130 bp and 120 bp. A PCR product containing the homozygous mutant genotype (GG, 
referred to as 1650GG in this report) of the SNP A1650G was undigested following restriction 
digest reaction resulting in a 250 bp undigested fragment. A PCR product containing the 
heterozygous mutant genotype (AG, referred to as 1650AG in this report) of the SNP 
A1650G resulted in 3 restriction fragments of 250 bp, 130 bp and 120 bp. HAEIII restriction 
digestion was used to detect the SNP C1604G: a PCR product containing the wild type 
genotype (CC) of the SNP C1604G would result in 5 restriction fragments of 110 bp, 40 bp, 
36 bp, 28 bp and 19 bp.  A PCR product containing the mutant homozygous genotype (GG) 
of the SNP C1604G would result resulting in 4 restriction fragments of 138 bp; 40 bp, 36 bp, 
and 19 bp.  A PCR product containing the heterozygous genotype (CG) of the SNP C1604G 
would result in 3 restriction fragments of 138 bp, 110 bp and 40 bp. 
 
3.2.3 Genotyping of SNPs in the TNPO3 and PSIP1 genes using TaqMan Assays 
A final volume of 15 µl of 20X homemade master mix which was 5 µl of 1X PCR Buffer 
containing 1.5 mmol/µl MgCl2 (Roche), 4 µl of 2.5 mmol/µl MgCl2 (ABI‟s), 0.31 µl of 80% 
Glycerol, 0.05 µl of 50% Tween 20, 3.4 µl of distilled sterile water, 0.27 µl 10 mmol/µl dNTPs, 
0.11 µl of 1µM SFHD, 0.05 U/µl DNA polymerase, and 0.068 U/µl of Taq Gold (Roche) and 
AOD/ABD/TaqMan probes was prepared. TaqMan Assays were performed in 384 well plates 
and each well contained 13 µl of the homemade master mix and 2 µl of 10 ng/µl DNA 
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sample. This was amplified at 95 ºC for 3 minutes, 40 cycles of 92 ºC for 15 seconds and 60 
ºC for 60 seconds. 
 
TaqMan assays were used to genotype intronic and exonic haplotype tagging (ht) SNPs in 
TNPO3 gene and only intronic ht SNPs in PSIP1 gene. SNP rs61744944 which is in the exon 
region of PSIP1 was also included in this analysis. The 6  intronic and 2 exonic ht SNPs in 
TNPO3 were rs13242262, rs2305325, rs11768572, rs1154330, rs35060568, rs8043, 
rs6957529 and rs10229001 all available from NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP) and HapMap databases (http://www.hapmap.org) 
selected by considering location, spacing, and allele frequency of at least 10% (Table 3.2.3).  
 
Table 3.2.3. Showing the rs numbers of TNPO3 and PSIP1 SNPs and TaqMan Assays 
Gene SNP 
number 





TaqMan Assay ID Number or Assay 
sequences 
TNPO3 SNP1 regulatory rs13242262 C_2691237_10 
 SNP2 intron rs2305325 C_7877026_1 
 SNP3 intron rs11768572 C_31283360_10 
 SNP4 intron rs1154330 C_8338470_10 
 SNP5 exon rs35060568 C_22273560_10 
 SNP6 exon rs8043 C_8336193_1 
 SNP7 intron rs6975529 C_31283343_10 
 SNP8 intron rs10229001 C_2691246_10 
PSIP1 SNP1 intron rs2277191 C_15883595_10 
 SNP2 intron rs10283923 C_29529242_10 
 SNP3 intron rs12339417 C_31936110_10 
 SNP4 intron rs1033056 C_2757693_20 









The 4 intronic ht SNPs in PSIP1 were rs2277191, rs1033056, rs12339417 and rs10283923, 
all available in the databases mentioned above and were selected as per aforementioned 
criteria (Table 3.2.3). The ht SNPs were chosen because they are all ht SNPs for TNPO3 
and PSIP1 genes in the Yoruba population from Nigeria (http://www.snp.cshl.org). The 
exonic SNP rs61744944 was selected based on its association with HIV-1 clinical outcomes 
in the preliminary analysis of the sequencing data (section 4.3.2.2). The SNPs in both 
TNPO3 and PSIP1 genes were genotyped in 247 patient samples (195 SNs and 52 SPs) 
from the CAPRISA AI 002 cohort and 403 patient samples from the Sinikithemba cohort. 
 
Genotyping was performed by TaqMan SNP assay as per manufacturer‟s protocol (Applied 
Biosystems). TaqMan assays were obtained from the Assay-by-Demand service of Applied 
Biosystems (http://www.appliedbiosystems.com). Eight negative controls which contained 
water instead of DNA were included in each plate to monitor the potential of PCR 
contamination. Samples were genotyped in duplicate and genotypes obtained were free of 
water contamination or of inconsistencies between duplicates. 
 
3.2.4 Peripheral blood mononuclear cell (PBMC) sample processing and RNA isolation 
A modified Trizol method [272] was used to extract RNA from peripheral blood mononuclear 
cells (PBMCs). In this modified method, PBMCs were homogenized in 1ml Trizol reagent, 
followed by incubation for 10 minutes at ambient temperature. The homogenate was 
centrifuged @ 12,000 revolutions per minute (rpm) for 10 minutes at 4 ºC and a 200µl 
volume of chloroform was added to the same tube. The combination of chloroform and 
84 
 
centrifuged homogenate was thoroughly mixed by shaking the tube vigorously for 30 
seconds followed by incubation at room temperature for 5 minutes and centrifugation @ 
12,000 rpm for 15 minutes at 4oC.  
 
The supernatant which contained the total RNA was transferred into a new 1.5ml eppendorf 
tube. 500µl isopropanol and 1.5µl glycogen was added into this new tube to precipitate out 
the total RNA and the tube was incubated at room temperature for 10 minutes. This was 
followed by centrifugation for 10 minutes at 4 ºC @ 12,000 rpm. The supernatant was 
discarded leaving the total RNA pelleted at the bottom of the tube. The RNA pellet was 
washed by resuspending it in 1ml of 75% ethanol and this RNA suspension was centrifuged 
@ 12,000 rpm for 5 minutes at 4 ºC. The supernatant was discarded and the RNA pellet was 
air dried then dissolved in 30µl nuclear free (DEPC) water. 
 
The RNA concentration was quantified using a NanoDrop spectrophotometer 2000 (Thermal 
Scientific) and the purity of RNA was determined by the ratio of absorbance at the 
wavelength of 260 (A260) and 280 (A280). The samples were used only if the A260/A280 ratio 
was 1.90 or greater. All RNA samples were DNAse treated using the fermentas DNASE kit 
(Fermentas cat. no. EN0521).  
 
3.2.4.1 Reverse Transcription 
An amount of 1 μg of the total RNA from each sample was reverse transcribed using the 
iScript cDNA synthesis kit (Biorad) as per the manufacturer‟s instructions. Briefly, the 
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reaction mixture was constituted of 4µl of 5x iScript reaction mix, 1µl of iScript reverse 
transcriptase, 1µg RNA and DEPC water to a final volume of 15µl. The above reaction 
mixture was prepared on ice in a sterile PCR tube. The reaction mixture was incubated for 5 
minutes at 25 ºC, 42 ºC for 30 minutes, and 85 ºC for 5 minutes and held at 4 ºC for 45 
minutes in the Gene Amp 9700 PCR System (Applied Biosystems, California, USA). 
 
3.2.4.2 Quantitation of RNA using real-time PCR. 
The PCR primers and cycling conditions used for glyceraldehyde 3-diphosphate 
dehydrogenase (GAPDH) and CypA real-time quantitative PCR are provided in section 
4.1.1.5 below. GAPDH is a house keeping gene and was determined to be the most suitable 
reference gene based on PCR efficiency. Each PCR reaction consisted of 3 mmol/μl MgCl2, 
0.5pmol/µl of the respective primers for GAPDH and CypA (Table 4.1.1.5), 1μl Fast Start 
SYBR Green I (Roche), 1 μg cDNA and water (10 μl total volume) was prepared. Reactions 
were run on a Roche LightCycler v1.5 (1 cycle at 95 ˚C for 10 min), then 45 cycles of 
denaturation, annealing and extension (see section 4.1.1.1 for details). Melting curve 
analysis was used to confirm the amplification specificity. Serial dilutions of cDNA from total 















4.1 Genetic Variant A1650G of Cyclophilin A Gene (PPIA) Accelerate Progression to 
AIDS in Black South Africans 
HIV-1 is an obligate intracellular parasite and therefore it relies, on cellular cofactors for 
efficient and productive infection. CypA, also known as peptidyl prolyl isomerase A (PPIA), is 
a cytoplasmic factor that is essential for efficient infection of HIV-1 [134, 141, 146]. CypA is a 
member of the cyclophilin family, members of which all possess peptidyl-prolyl cis/trans 
isomerase activity. Peptidyl prolyl cis/trans isomerases catalyze the cis/trans isomerization of 
prolyl peptide bonds and are believed to be involved in protein folding [72]. This suggests 
that CypA has a possible role in uncoating of the viral core following entry into the cytoplasm. 
CypA is incorporated into the HIV-1 virion capsid through the direct binding between prolyl 
peptide bond located in a proline-rich loop of the fourth and fifth helices of the HIV-1 capsid 
and the active sites of CypA [129, 273].  
 
CypA has long been known to enhance HIV-1 replication in host cells [134, 135] (by 
convention, we refer to the protein as CypA and the gene as PPIA). Disruption of CypA 
incorporation, either by HIV-1 Gag mutations or by cyclosporine A, an immunosuppressive 
drug that prevents HIV-1 Gag binding to CypA, leads to an attenuation of HIV-1 infectivity 
[134, 274]. HIV-1 replication was significantly inhibited in CypA-null human CD4+ T cells, in 
which the PPIA was deleted through homologous recombination [145]. CypA is therefore an 
important host factor required for efficient and productive HIV-1 infection. It has also been 
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postulated that binding of CypA to capsid protects HIV-1 from an unknown restriction factor in 
humans [275]. 
 
Genetic polymorphisms in the regulatory region of PPIA gene (fig. 4.1) have been implicated 
in HIV-1 infection and pathogenesis [61, 73, 74]. Bleiber et al. reported an association 
between the minor allele (G) of SNP A1650G (1650G) and rapid disease progression in the 
Swiss Caucasian population [61]. Subsequently, An et al. reported that the same allele, 
1650G was more frequent among SPs suggesting that the 1650G might be associated with 
increased susceptibility to HIV-1 infection in the American [73]. However, the 1650G was 
neither significantly associated with susceptibility to HIV-1 infection nor disease progression 
in this study [73]. Instead, this group found a significant association of the minor allele (C) of 
SNP C1604G (1604G) with accelerated progression to AIDS in the American population. 
 
In another study, Rits et al. found the frequency of the 1650G to be significantly increased in 
high-risk seronegative (HRSN) group compared to SP group of the Amsterdam Cohort 
studies (ACS) and they also reported reduced levels of CypA mRNA expression in PBMCs 
from SN group [74]. According to this report, these findings suggested that the 1650G might 
be associated with reduced susceptibility to HIV-1 infection in participants of the ACS. It is 
important to note that the data reported by this this group [74] regarding the susceptibility to 
HIV-1 infection is in sharp contrast with the previous report [73]. Nevertheless, this group 
found an association between the 1604G and accelerated disease progression, measured by 







Figure 4.1. Gene Map, SNPs, and Haplotypes in the Human PPIA on Chromosome 7p13. 
Coding exons are marked by green blocks, and 59 and 39 UTRs by light green blocks. 
Hatched black boxes represent Alu repeats. Haplotype structure and frequencies are shown 
in the middle panel. The corresponding nucleotides in the chimpanzee and allele frequencies 
of the SNPs are presented in the bottom panel. MAF: minor allele frequency of SNPs. AA: 
African Americans. EA: Europeans Americans [73]. 
 
The data obtained for the role of PPIA genetic variation in susceptibility to HIV-1 infection and 
disease progression were inconsistent [61, 73, 74]. The plausible reason for these 
discrepancies could be attributed to different cohort designs. Bleiber et al. studied the effect 
of PPIA genetic variation in a cohort of Swiss origin [61], An et al. studied the effect of PPIA 
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genetic variation in cohorts of American origin [73] while Rits et al. investigated the effect of 
PPIA genetic variation in cohorts of Amsterdam origin [74]. In the current study, we 
hypothesized that the differences observed in the effect of PPIA genetic variation on HIV-1 
disease outcome could be due to different population groups (or study cohorts). Therefore, in 
the present study we wanted to test the effect of PPIA genetic variation, SNPs A1650G and 
C1604G in particular, on susceptibility to HIV-1 infection and disease progression in Black 
South African women from the CAPRISA AI 002 study cohort. Using some patient samples 
from the same cohort, we also studied the impact of PPIA genetic variation on CypA mRNA 
expression levels. 
 
4.1.1 Materials and Methods 
Study participants. A cohort of black South African women (CAPRISA AI 002) [269] was 
used for this study (see section 3.1 for detailed description). Ethical approval for this study 
was obtained from Biomedical Research Ethics Committee of the University of KwaZulu-
Natal. All participants provided written informed consent. 
 
4.1.1.1 Genotyping for regulatory SNPs (A1650G and C1604G) in the PPIA gene in the 
CAPRISA AI 002 cohort 
DNA samples from 47 seropositive (SP) and 168 seronegative (SN) participants from the 
CAPRISA AI 002 cohort were available for genotyping. For the analysis of the C1604G and 
A1650G polymorphisms in the promoter region of the PPIA gene, DNA samples were 
amplified by PCR using Taq DNA polymerase (Invitrogen) in the presence of 1X AmpliTaq 
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Gold PCR buffer, 1.25 mmol/µl MgCl2, 0.4mmol/µl dNTPs, 10 ρmol/µl of each primer pair 
CYPAex-1s (5‟-AAGTCGCAGACCCGATTG-3‟) and CYPAex-1a (5‟-
ACTTTCTGGGCCCCATTC-3‟). The following amplification cycles were used: 10 min 95 ºC; 
35 cycles of 30 s 94 ºC, 30 s 60 ºC, 45 s 72 ºC; 5 min 72 ºC. Subsequently, PCR products 
were subjected to a restriction digest with either RsaI or HAEIII (overnight at 37oC; New 
England Biolabs) to detect polymorphisms and analyzed on a 4% agarose gel (see section 
3.2.2).  
 
4.1.1.2 CypA expression analysis and in vitro replication assay. 
Peripheral blood mononuclear cells (PBMCs) were isolated from 30 SNs and 28 SPs from 
the CAPRISA AI 002 cohort as previously described [276] and these participants were 
genotyped for SNP A1650G. There were at least two study time points available for each of 
the participants in the primary HIV-1 infection phase and a total of 75 separate samples were 
analyzed for this group. Samples were available before and after HIV-1 infection for 13 of SP 
participants. 
 
4.1.1.3 Sample processing, viral load quantification and CD4 cell enumeration. 
PBMCs were isolated by Ficoll-Histopaque (Sigma) density gradient centrifugation from 
blood within 6 hours of phlebotomy and frozen in liquid nitrogen until use.  Viral load was 
determined using the automated COBAS AMPLICOR HIV-1 Monitor Test v1.5 (Roche). CD4+ 
T cells were enumerated by using the Multitest kit (CD4/CD3/CD8/CD45) on a four-




4.1.1.4 RNA isolation and analysis. 
For all samples, RNA was extracted immediately after thawing and counting of PBMCs 
without in vitro stimulation. RNA was extracted from 2 x 106 PBMCs using the TRIzol LS 
Reagent (Invitrogen). The total RNA concentration was quantified and samples were used 
only if the A260/A280 ratio was 1.90 or greater. All RNA samples were DNAse treated.  1 μg of 
total RNA from each sample was reverse transcribed using the iScript cDNA synthesis kit 
(Biorad). 
 
4.1.1.5 Real-time PCR RNA quantitation. 
Following RNA isolation and cDNA synthesis, real time quantitative (q) PCR was performed 
to measure the CypA mRNA expression levels. For this experiment GAPDH was used as the 
reference gene based on its PCR efficiency. PCR primers and cycling conditions used for 
GAPDH and CypA real-time qPCR are shown in Table 4.1.1.5.  Each PCR reaction consisted 
of 3 mmol/μl MgCl2, the respective primers 0.5 pmol/μl for GAPDH and CypA, 1μl Fast Start 
SYBR Green I (Roche), 1 μg cDNA and water (10 μl total volume). Reactions were run on a 








Table 4.1.1.5. Primers and cycling conditions used in real time qPCR for CypA expression 
assay 
GAPDH: Housekeeping gene, glyceraldehyde 3-diphosphate dehydrogenase 
CypA: Cyclophilin A 
F: forward primer 
R: reverse primer 
 
To confirm amplification specificity, the PCR products were subjected to a melting curve 
analysis. Serial dilutions of cDNA synthesized from total RNA were made for each target 
gene.  These serial dilutions were then used to create standard curves for quantitative 
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CypA NM_021130 F: 5‟-GTCAACCCCACCGTGTTCTTC-3‟ 
 
 
R: 5‟-TTTCTGCTGTCTTTGGGACCTTG -3‟ 
 
(95 ºC, 6 s), (60 






4.1.1.6 Viral infection. 
Replication capacity of HIV-1 in PBMCs (2x106) isolated from healthy 26 SNs that were 
genotyped for A1650G was investigated. 8 1650AA wild type genotypes and 18 AG/GG 
mutant genotypes were placed in a 12-well plate in R20 and incubated for 3 days at 37oC, 
5% CO2. Following stimulation with IL2, cells were washed with R10 and then infected with 
HIV IIIB (NIH AIDS Reagent Repository) by spinoculation (2h, 2500 RPMs, 37oC) at 2x105 
cells/well in a 96-well plate.  Virus was subsequently removed; cells were washed once, and 
then allowed to incubate for an additional 2-7 days before analysis of CypA expression real-
time PCR. Cell culture supernatants from day 2 and 7 samples were harvested and analyzed 
by p24 ELISA (Becton Dickinson). 
 
Statistical analysis. The difference in allele frequency distribution between the SN and SP 
group was determined by Fisher‟s exact test (FET) for the SNP A1650G to test the null 
hypothesis that allele frequencies were the same in the two groups.  
 
The effect of the SNP A1650G on HIV-1 viral load and CD4+ T cell count was determined 
using a Generalized Estimating Equation (GEE) model [277] taking into account longitudinal 
measures for each participant.  Viral loads were log-transformed and the square root of CD4+ 




Kaplan-Meier survival statistics and the Cox proportional hazards model (Cox model) were 
used to assess the effect of each SNP on time to HIV-1 infection after enrollment and on the 
rate of progression to AIDS defined as CD4+ T cell decline to less than 350 cells/μl 
(CD4<350). Decline in CD4 levels was determined and compared for the group with one or 
two copies of the minor allele to a reference group with two copies of the major allele 
(dominant genetic model).  The significance of genotypic associations and relative hazard 
(RH) was determined by unadjusted Cox regression analysis for the dominant genetic model.  
 
CypA mRNA expression levels were compared between SNs and SPs by performing dot plot 
graphical representation, nonparametric statistical analysis, and correlation (Pearson). 
Values were expressed as median values. Differences between the 2 groups were evaluated 
using Dunn‟s multiple comparison test, whereas the Mann-Whitney U test was used for any 
2-group comparisons. The software used for the analysis was SAS version 9.1.3 (SAS 
Institute Inc., Cary, NC). A result was considered significant if the P-value was < 0.05. 
 
4.1.2 Results 
4.1.2.1 Genotyping for regulatory SNPs (A1650G and C1604G) in the PPIA gene. 
Although there are many SNPs in the PPIA gene [41], in this study we focused only on two 
SNPs, A1650G and C1604G because they have been shown to have an association with 
disease outcome in the previous studies [61, 73, 74]. DNA was extracted from buffy coats 
obtained from 215 participants in the CAPRISA AI 002 cohort according to the 





















Figure 4.1.2.1.1. Analysis of DNA extraction by 0.8% agarose gel electrophoresis. MWM III, 
DNA ladder molecular weight marker III (Fermentas). Numbers 1-26, represents the lanes in 
which extracted DNA was loaded for analysis. Lane 6 and lane 26 contains negative controls 
that contained water instead of DNA. 
 
215 (47 SP and 168 SN) out of 279 buffy coats samples gave good quality DNA yields 
suitable for genotyping analysis. SNPs A1650G and C1604G which are in the promoter 
region of the PPIA gene were analyzed by PCR-RFLP method (section 3.2.2). Firstly the 







Figure 4.1.2.1.2. Polymerase chain reaction (PCR) amplification of DNA extracted from buffy 
coats obtained from study participants. 1kb DNA molecular weight marker (Fermentas) was 
used. <- PCR amplified DNA -> indicate the lanes containing DNA that was amplified by 
PCR. NC represents negative control. 
 
Following PCR amplification, the PCR products were then subject to restriction digest by 
restriction enzymes for RFLP analysis. For this analysis two restriction enzymes RsaI and 
HAEIII were used for analyzing SNPs A1650G and C1604G, respectively. Restriction of the 
PCR products using RsaI yielded distinct restriction fragments which are seen as DNA bands 
after 4% agarose gel electrophoresis analysis  (fig. 4.1.2.1.3A). After restriction digestion with 
RsaI, a PCR product containing homozygous wild type 1650AA genotype yielded two 
restriction fragments of 130 bp and 120 bp in size. Homozygous mutant 1650GG genotype 
did not get digested yielding undigested PCR product of 250 bp in size. Consequently, a 
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PCR product containing heterozygous 1650AG genotype yielded three restriction fragments 
of 250 bp; 130 bp and 120 bp in size. These results demonstrate that the homozygous 









Figure 4.1.2.1.3. Restriction fragment length polymorphism (RFLP) analysis of PCR 
amplified DNA. RFLP analysis was performed using two restriction enzymes: A, RFLP 
banding patterns following restriction with RsaI enzymes. B, RFLP banding patterns following 
restriction with HEAIII enzymes. 
 
In contrast, RFLP analysis after restriction with HEAIII shows uniform banding patterns (fig. 
4.1.2.1.3B) suggesting that participants in the CAPRISA AI 002 study cohort were not 
polymorphic at C1604G locus of the PPIA gene. Based on these findings, the SNP C1604G 




4.1.2.2 Influence of SNP A1650G on CD4+ T cell counts and viral load.  
Rits et al. did not find an association between the SNP A1650G and CD4+ T cell counts or 
plasma viral RNA loads in the Amsterdam Cohort of studies (ACS) [74]. In this study we 
therefore tested the influence of the SNP A1650G on CD4+ T cell counts and viral loads in 
the CAPRISA AI 002 cohort. The approximate time of HIV-1 infection was known for SPs in 
the CAPRISA AI 002 cohort [269]. Since viral loads and CD4+ T cell counts fluctuate 
significantly during acute HIV-1 infection, we analyzed the data in two intervals post infection, 
0-3 months (acute phase) and 3-12 months (early chronic phase) to detect possible 






Figure 4.1.2.2. The association between different genotypes of the SNP A1650G and CD4+ 
T cell counts and viral loads during the primary HIV-1 infection.  A and B show the 
association of different genotypes with square root CD4+ T cell counts and log viral loads 
during acute phase (0-3 months) of infection, respectively. C and D show the association of 
different genotypes with square root CD4+ T cell counts snd log viral loads during early 
chronic phase (3-12 months) of infection, respectively. AA wild type genotype and 
AG/GGmutant genotypes. 
 
A dominant model analysis using GEE showed that the 1650G was significantly associated 
with lower CD4+ T cell counts (p=0.02) (fig. 4.1.2.2A) and higher viral loads (p<0.01) (fig. 
4.1.2.2B) during the acute phase of infection. Interestingly, similar results were observed 
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during the early chronic phase of infection where the 1650G was significantly associated with 
lower CD4+ T cell counts (p<0.01) (fig. 4.1.2.2C) and higher viral loads (p<0.01) (fig. 
4.12.2D).  
 
Although An et al. did not find significant association of the1650G with clinical outcomes in 
either European American or African American [73], Bleiber et al. reported an association of 
the 1650G with rapid CD4 cell depletion in a Swiss Caucasian HIV-1 cohort and a trend 
toward higher in vitro HIV-1 replication [61]. Interestingly, the results obtained from the 
current study are consistent with the results obtained from a Swiss Caucasian HIV-1 cohort 
[61]. The current study reports the association of the 1650G with enhanced HIV-1 replication 
as reflected by significantly higher viral loads and lower CD4+ T cell counts during primary 
HIV-1 infection (fig. 4.1.2.2). 
 
4.1.2.3 Effects of SNP A1650G on disease progression 
Next, we tested the influence of the SNP A1650G on disease progression in the SP group. 
Kaplan Meier and Cox proportional hazard analysis were used to test for potential differences 
in CD4+ T cell decline between individuals who carried the 1650AA or 1650AG/GG genotype 
(dominant model). Our results show borderline significant association between the 









Figure 4.1.2.3. Kaplan Meier survival curves showing differences in rates of progression to 
CD4+ T cells below 350 cells per ml between individuals who carried the 1650AA or 
1650AG/GG genotype (dominant model). 
 
 
This association supports the earlier observations (fig. 4.1.2.2) that the 1650G is associated 









Table 4.1.2.3. Effect of the PPIA SNP A1650G on HIV-1 Acquisition Risk 
 
 
Although the 1650G frequency was higher in the SP group as compared to the SN group, 
this difference was not significant (p=0.31) (Table 4.1.2.3). Unlike the previous studies [73, 
74], our results suggest that the 1650G may not be associated with susceptibility to HIV-1 
infection in this setting  
 
4.1.2.4 Effect of 1650G on CypA expression levels in vivo. 
Next we analyzed whether the SNP A1650G of the PPIA gene influenced CypA mRNA 
expression levels in vivo. We performed quantitative RT-PCR to measure CypA mRNA levels 
in 30 SNs and 28 SPs. The data obtained from this experiment indicates that PBMCs 
obtained from SPs had elevated levels of CypA mRNA expression compared to PBMCs 
obtained from SNs, however, the difference was not significant (fig. 4.1.2.4A).  For 13 of SPs, 
samples pre- (baseline) and post-HIV-1 infection were available for analysis. Baseline 
PBMCs from seroconverters had higher CypA expression compared to PBMC from non-
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seroconverters but this was not significantly different (fig. 4.1.2.4B). These results provide no 











Figure 4.1.2.4. CypA mRNA Expression in peripheral blood mononuclear cells (PBMCs) 
represented as the normalized ratio of CypA to GAPDH. A, Expression of CypA mRNA in 
PBMCs obtained from SNs versus SPs. B, Expression of CypA mRNA in PBMCs obtained 
seroconverters versus nonseroconverters. C, Expression of CypA mRNA as modulated by 
different genotypes among SNs. D, Expression of CypA mRNA as modulated by different 





CypA expression between the 1650AA and 1650AG/GG genotypes was not significantly 
different amongst the SN group (fig. 4.1.2.4C). Interestingly, the 1650G was significantly 
associated with elevated levels of CypA mRNA expression post HIV-1 infection (p<0.01) (fig. 
4.1.2.4D) suggesting that the 1650G drives higher expression of CypA mRNA levels which in 
turn promotes HIV-1 replication in vivo in the black South African cohort.  
 
4.1.2.5 Effect of 1650G on CypA expression levels and HIV-1 replication in vitro 
Next we analyzed whether the SNP A1650G was associated with altered CypA expression 
levels in vitro. Again, we performed quantitative RT-PCR on CypA mRNA levels in PBMCs of 
26 SN (or highly exposed but persistently seronegative (HEPS)) group, genotyped for 
A1650G SNP. Pre-HIV-1 infection expression levels of CypA were significantly higher in 
PBMC genotyped for the1650G compared to CypA expression levels in PBMC harboring the 
1650AA genotype (p<0.01) (fig. 4.1.2.5A). At day 2 post infection, we observed a significant 






Figure 4.1.2.5. Expression of CypA mRNA in PBMCs represented as the normalized ratio of 
CypA to GAPDH. PBMCs were obtained from highly exposed but persistently seronegative 
(HEPS). A, expression levels of CypA mRNA pre-and post-HIV-1 infection of PBMCs. B, 
replication assays of HIV-1 in PBMCs harboring different genotypes of the SNP A1650G. 
 
Interestingly, at day 7 post infection, our results demonstrated that the expression levels of 
CypA in PBMCs genotyped for the 1650G were restored to significantly higher levels 
(p<0.01) (fig. 4.1.2.5A). These results demonstrated that CypA expression is altered by HIV-
1 infection. Elevated levels of CypA expression from day 7 onwards support the findings 
presented above that 1650G promotes HIV-1 replication and rapid disease progression.  
 
In order to determine when does the 1650G start to have an impact on HIV-1 replication, we 
analyzed the replicative capacity of HIV-1 in IL2 stimulated PBMC from 26 HEPS individuals 
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with known genotypes for the SNP A1650G. IL2-stimulated PBMC were inoculated with 5ng 
of NL4.3 per 2X106 cells. Subsequently, virus replication was assessed by measuring p24 
antigen levels in the culture supernatant every other day for 7 days. Similar to the previous 
study [74], our results did not show significant differences in p24 production at any time point 
during the culture period, irrespective of the genotype of the SNP A1650G (figure 4.1.2.5B). 
These results suggest that the effect of the SNP A1650G is not shown in short-term tissue 
culture and therefore its effect may be subtle rather than dramatic.  
 
4.1.3 Discussion and Conclusion 
The role of CypA in promoting HIV-1 replication was initially established through extensive in 
vitro experiments [134, 135, 145, 274]. Subsequent studies validated CypA as an important 
cellular cofactor of HIV-1 by identifying SNPs within the PPIA gene that are associated with 
HIV-1 disease outcome [61, 73, 74]. Although numerous SNPs within the PPIA gene have 
been implicated to HIV-1 clinical outcome [73], this study focused only on one SNP, A1650G, 
because it was polymorphic in a cohort of black South African women (CAPRISA AI 002). 
The minor allele (1650G) was associated with enhanced in vivo HIV-1 replication as evident 
from significantly higher viral loads and lower CD4+ T cell counts following HIV-1 infection in 
the CAPRISA AI 002 cohort. These results corroborate the data obtained from a Swiss 
Caucasian HIV-1 cohort and in vitro data which showed a trend towards higher HIV-1 
replication [61]. However, the 1650G was not associated with disease progression in either 




While there was no evidence of association between the 1650G and susceptibility to HIV-1 
infection in both the American and Swiss cohorts [61, 73], results obtained from the 
Amsterdam cohort suggest that 1650G may be associated with protection against HIV-1 
infection [74]. In this study, we report that the 1650G was similarly distributed between SN 
and SP groups of the CAPRISA AI 002 cohort. Thus, the role of the 1650G in susceptibility to 
HIV-1 infection remains inconclusive and warrants further investigation. The discrepancy in 
the observed phenotypes could be attributed to the fact that these studies used populations 
from different geographical areas. There are differences in allele frequencies among potential 
disease influencing gene variants between ethnic groups and geographically separated 
populations [107]. 
 
The entire PPIA gene was re-sequenced and no genetic variation was found in the coding 
sequence of the PPIA gene and the dbSNP database has no documented records of 
variation in the coding sequence of the PPIA gene [73]. This suggests that differential genetic 
impact of PPIA SNPs on HIV-1 replication and disease progression are likely due to the 
1650G affecting protein levels since the SNP A1650G is in the regulatory region of PPIA 
gene. Although CypA mRNA expression levels are altered by HIV-1 infection, our results 
demonstrated that PBMCs genotyped for the 1650G expresses higher levels of CypA mRNA 
than PBMCs genotyped for wild type genotype, 1650AA. Rapid depletion of CD4 cells to less 
350 cell/ml could be partially attributed to higher expression levels of CypA since participants 




The replicative capacity of HIV-1 (NL4.3) in IL2 stimulated PBMCs was higher in PBMCs 
genotyped for 1650G as was measured by p24 production. However, there was no significant 
difference in the amount of p24 produced between PBMCs genotyped for 1650AA and 
1650AG/GG. Lack of significant difference could be attributed to a shorter period (7 days) of 
incubation of PMBC with HIV-1.  
 
In summary, we demonstrate that SNP A1650G is associated with higher HIV-1 replication 
and rapid CD4+ T depletion in black South Africans. These findings corroborate the 
understanding that the genetic variation of the PPIA gene influences HIV-1 disease 
progression [61, 73] and further confirm that CypA is a critical host protein crucial for efficient 
HIV-1 replication. Small molecule inhibitors may be designed to block the interaction between 




4.2 The Influence of Genetic Variation in the TNPO3 Gene on Susceptibility to HIV-1 
Infection and Disease outcomes 
HIV-1 has the capacity to infect nondividing cells, including cells of monocyte/macrophage 
lineage. The early events of HIV-1 replication include reverse transcription to synthesize viral 
copy DNA (cDNA) from the RNA genome and subsequent integration of viral cDNA into the 
cellular chromosome. Reverse transcription and integration of HIV-1 cDNA occur within the 
context of higher-molecular-weight nuclear protein complexes derived from viral cDNA, 
proteins and host proteins. Cellular chromosome resides within the nucleus and therefore, 
HIV-1 must enter the nucleus to replicate successfully [32].  
 
However, the interior of the nucleus is separated from the cytoplasm by a double-layer 
nuclear membrane possessing nuclear pore complexes that allow the trafficking of molecules 
between the cytoplasm and the nucleus in interphase (nondividing) cells [278]. Nuclear pores 
allow the diffusion of ions and molecules smaller than 9 nm in diameter. Other studies have 
reported nuclear pores to facilitate passage of larger molecules up 39 nm in diameter under 
certain conditions (reviewed in [31]. At 56 nm [30], viral cDNA, packed in the preintegration 
complex (PIC) grossly exceeds the diffusion limit and yet HIV-1 PIC is actively transported 
during interphase [32, 33], reflecting its ability to efficiently infect nondividing cells.  
 
A number of HIV-1 proteins–matrix (MA), viral protein R (Vpr), integrase (IN), and the central 
DNA flap–constituting the PIC have been implicated in nuclear import. However, this aspect 
of HIV-1 biology remains highly controversial with reports both supporting and refuting the 
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role of these viral proteins in the nuclear import (reviewed in [75, 206, 279]). In addition to 
HIV-1 PIC proteins, host proteins, including the importin α/importin β heterodimer [35, 280, 
281], importin 7 [280, 282, 283], NUP153 [284], and transportin-SR2 (TRNSR2) [178, 285] 
have been implicated in HIV-1 nuclear transport. 
 
TRN-SR2 is a member of the karyopherin protein family that imports serine/arginine-rich 
splicing factors (SR proteins) into the nucleus [157]. TRN-SR2 has recently been identified as 
a cellular protein that interacts with HIV-1 integrase (IN) to import HIV-1 PIC into the nucleus 
[160, 285]. Recently, Engelman‟s group published results that discounted the important role 
for IN in determining the requirement for transportin 3 (TNPO3) during infection and 
highlighted a dominant role for CA in this aspect of HIV-1 biology [32]. The gene and its 
protein are referred to as TNPO3 and TRN-SR2, respectively (section 1.6.2). 
 
Previous research has shown that the disruption of this interaction inhibits HIV-1 replication 
in vitro. TRN-SR2 depletion significantly inhibited HIV-1 replication [67, 68, 160]. Christ et al. 
demonstrated that the inhibition was due to the blocking of PIC at nuclear import [160], 
indicating a potential role of TRN-SR2 in nuclear import of HIV-1 PIC. The role of TRN-SR2 
in HIV-1 infection, so far, has been studied in vitro. 
 
Identification of genetic variation and its association with disease outcome is a powerful way 
of validating the in vitro data. Previous studies have used this approach to identify genetic 
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variants that affect susceptibility to HIV-1 infection and disease progression. A 32 base pair 
deletion in the portion of the human CCR5 open reading frame encodes a truncated protein, 
designate Δ32. Individuals who are homozygous for CCR5Δ32 gene are protected against 
HIV-1 infection [286] and AIDS progression is delayed in heterozygous individuals [47, 49, 
286-288]. 
 
Association of genetic variation and disease outcome is a powerful tool for validating the 
importance of a gene or gene product in HIV-1 infection and pathogenesis. Since the 
association of genetic variation of the TRN-SR2 gene (TNPO3) and HIV-1 disease outcome 
had never been studied before, the current study investigated the association of genetic 
variation in the TNPO3 with susceptibility to HIV-1 infection and disease progression. 
 
4.2.1 Materials and Methods 
Study participants. Two South African cohorts CAPRISA AI 002 [269] and the Sinikithemba 
[271] were used for this study (see section 3.1).   
 
4.2.1.1 Genotyping of SNPs in TNP03 gene in the CAPRISA AI 002 Participants  
6 intronic and 2 exonic haplotype tagging (ht) SNPs rs13242262, rs2305325, rs11768572, 
rs1154330, rs35060568, rs8043, rs6957529 and rs10229001 in the TNPO3 gene selected as 
described in section 3.2.3 were genotyped in 247 patient samples (52 SPs and 195 SNs) 
from the CAPRISA AI 002 cohort. The ht SNPs were chosen because they are ht SNPs for 
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the TNPO3 gene in the Yoruba population from Nigeria (http://www.snp.cshl.org). 
Genotyping was performed using the TaqMan SNP assay according to the manufacturer‟s 
protocol (Applied Biosystems). TaqMan assays were obtained from the Assay-by-Demand 
service of Applied Biosystems (http://www.appliedbiosystems.com). Eight negative controls 
which contained water instead of DNA were included in each plate to rule out PCR 
contamination. Samples were genotyped in duplicate and genotypes were accepted after 
confirmation of no contamination or inconsistencies between duplicates. 
 
4.2.1.2 Genotyping of the SNP rs1154330 of the TNPO3 gene in the Sinikithemba 
Participants  
Analysis of the TNPO3 gene genotyping results from the CAPRISA AI 002 cohort showed an 
association between the SNPs in the TNPO3 gene and HIV-1 outcomes. However, the 
interpretation of the data from the CAPRISA AI 002 cohort was complicated by a small 
sample size, only 52 SPs. Since the minor allele (G) of the SNP rs1154330 (rs1154330G) 
gave consistent results in the CAPRISA AI 002 cohort, we decided to extend the analysis of 
this SNP to a larger cohort of 450 HIV-1 chronically infected individuals from Sinikithemba 
cohort, to either confirm or refute the results obtained from the CAPRISA AI 002 cohort. 
Genotyping assays were performed as described above for CAPRISA AI 002 cohort. 
 
4.2.1.3 Statistical Analysis 
The differences in allele frequency distributions between the SP and SN groups were 
determined by Fisher‟s exact test (FET) for each SNP to test the null hypothesis that allele 
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frequencies were equally distributed between the SN and SP groups. The effect of each SNP 
on HIV-1 viral loads and CD4+ T cell counts was determined using a GEE model [246] which 
takes into account the longitudinal measures for each participant. Viral loads were log 
transformed and the square root of CD4+ T cell counts was used to normalize both CD4+ T 
cell count and viral load measurements.  
 
Kaplan-Meier survival statistics and the Cox proportional hazards model (Cox model) were 
used to assess the effect of each SNP on time to HIV-1 infection after enrollment in the 
CAPRISA AI 002 cohort and on the rate of CD4+ T cell decline to less than 350 cells/μl 
(CD4<350). The rate of CD4+ T cells decline was compared between the reference group 
(SPs containing the wildtype genotype) and a group with containing the mutant genotype 
(dominant genetic model) for each SNP. P<0.05 and P<0.0015 were considered to denote 
statistical significance before and after correction for multiple comparisons, respectively. 
Statistical significance after a Bonferroni correction for multiple comparisons is indicated by 





4.2.2.1 Description of TNPO3 variations 
The TNPO3 gene is approximately 100.25kb in length consisting of twenty two exons (fig. 
4.2.2.1). 6 intronic and 2 exonic ht SNPs available from dbSNP database 
(www.ncbi.nlm.nih.gov/SNP) were selected to genotype participants from the CAPRISA AI 








Figure 4.2.2.1. Locations of the TNPO3 single nucleotide polymorphisms (SNPs) on 
chromosome 7. Coding exons of a gene are marked with red lines. Minor allele frequencies 





The SNP rs1154330 was further genotyped in the Sinikithemba cohort. The genotypic 
frequencies of all SNPs conformed to the frequencies expected under Hardy Weinberg (HW) 
equilibrium (Table 4.2.2.1).  
 











rs13242262 SNP1 regulatory TA 0.55 0.35 
rs2305325 SNP2 intron 4 TA 0.86 0.22 
rs11768572 SNP3 intron 4 AC 5.84 0.03 
rs1154330 SNP4 intron 12 AG 0.11 0.12 
rs35060568 SNP5 exon 17 CA 21.52 0.10 
rs8043 SNP6 exon 21 AG 0.26 0.38            
rs6957529 SNP7 Intron 21 TC 12.00 0.05 
rs10229001 SNP8 Intron 21 T C 0.92 0.25 
Hardy Weinberg was calculated using the CAPRISA AI 002 cohort MAF- minor allele 
frequency 
 
4.2.2.2 Effect of the TNPO3 SNPs on Susceptibility to HIV-1 Infection in the CAPRISA AI 
cohort 
The study design of the CAPRISA AI 002 cohort allowed us to study the influence of genetic 
variation of the TNPO3 gene on susceptibility to HIV-1 infection. Firstly, we compared the 
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TNPO3 SNP allele frequency distribution between the SP and SN groups and did not find 
distortions in allele distribution between the groups as shown for SNP rs1154330G (fig. 
4.2.2.2A).  
 
Figure 4.2.2.2. Association of the minor allele (G) of SNP rs1154330 (referred to as 
rs1154330G) with susceptibility to HIV-1 infection in the CAPRISA AI 002 cohort. A, 
frequency distribution of the rs1154330G between the SP and SN groups. B, The 
rs1154330G represented by a red curve on the graph showed significant association with 
fast acquisition of HIV-1 infection compared to the wild type allele (rs1154330A) at this locus 
(HR = 3.24, P < 0.01). 
 
Kaplan-Meier survival analysis of time to HIV-1 acquisition and showed that the minor allele 
(G) of SNP rs1154330 (referred to as rs1154330G) was associated with faster acquisition of 
HIV-1 infection (HR 7.13, 95% confidence interval [CI]: 3.06 - 16.50; p<0.01, Cox model) (fig. 
4.2.2.2B). Although the rs1154330G was more frequent amongst SPs, this was not 
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statistically significant. No association was observed between HIV infection and the rest of 
SNPs (Table 4.2.2.2). 
 




Number (Frequency)                              
22 and 12 versus 11 (reference group)* 
HR (95% CI)             P - value 
rs13242262 
(SNP1) 
     TT     AT   AA   
SN 195 78 (0.4) 97 (0.5) 20 (0.10)   
SP 52 24 (0.46) 20 (0.38) 8 (0.15) 2.55 (1.12 – 5.81)           0.73 
rs2305325 
(SNP2) 
     TT     AT   AA   
SN 195 120 (0.59) 68 (0.36) 7 (0.038)   
SP 52 32 (0.62) 15 (0.29) 5 (0.09) 2.71 (1.15 – 6.31)            0.64 
rs11768572 
(SNP3) 
     AA     AC  CC   
SN          195 180 (0.92) 15 (0.08) 0 (0.00)   
SP 52 50  (0.96) 2 (0.04) 0 (0.00) 0.00 (0.00 – 0.00) 0.99 
rs1154330 
(SNP4) 
     AA     AG  GG   
SN 195 158 (0.81) 31 (0.16) 6 (0.03)   
SP 52 39 (0.75) 13 (0.25) 0 (0.00) 7.13 (3.06 – 16.50) <0.01 
rs35060568 
(SNP5) 
     CC     AC  AA   
SN 195 155 (0.79) 40 (0.20) 0 (0.00)   
SP 52 42 (0.81) 10 (0.19) 0 (0.00) 0.76 (0.18 – 3.21)  0.15 
rs8043 
(SNP6) 
     AA     AG  GG   
SN 195 102 (0.52) 69 (0.35) 24 (0.12)   
SP 52 23 (0.44) 20 (0.29) 9 (0.17) 2.09 (0.86 – 4.99)  0.91 
rs6957529 
(SNP7) 
     TT     CT  CC   
SN 195 172 (0.88) 23 (0.12) 0 (0.00)   
SP 52 47 (0.90) 5 (0.10) 0 (0.00) 3.41 (0.75 – 8.51)  0.81 
rs10229001 
(SNP8) 
     TT     CT  CC   
SN  195 108 (0.55) 74 (0.38) 13 (0.07)   






4.2.2.3 Effect of the TNPO3 SNPs on CD4+ T cell counts and viral loads in the CAPRISA AI 
002 Cohort 
Since the approximate date of infection was known for CAPRISA AI 002 cohort, we analyzed 
the data in two specific intervals, 0-3 months post infection (acute phase of infection) and 3-
12 months post infection (early chronic phase of infection). The influence of genetic variation 
on CD4+ T cell counts and viral loads was performed in these specific intervals because viral 
loads and CD4+ T cell counts fluctuate significantly during primary infection. The rs numbers 
instead of SNP numbers will be used below, please refer to the table above (Table 4.2.2.1) to 
find the corresponding SNP numbers for rs numbers. Dominant model analysis, using GEE 
which takes into account repeated measurements, showed that the minor alleles (A) and (C) 
of rs2305325 and rs11768572, respectively were significantly associated with higher CD4+ T 
cell counts during the acute phase of infection (fig. 4.2.2.3A). The minor allele (A) of 
rs2305325 was associated with lower viral loads whereas the minor alleles (C) of SNPs 
rs11768572, (G) of rs1154330 (referred to as rs1154330G), (A) of rs35060568 and (C) of 
rs6957529 were significantly associated with higher viral loads during acute phase of 
infection (fig. 4.2.2.3B).  
 
The rs2305325A and rs10229001C were associated with higher CD4+ T cell counts while the 
rs1154330G, rs35060568A and rs6957529C were associated with lower CD4+ T cell counts 




The rs10229001C was associated with lower viral loads while the rs1154330G, rs35060568A 
and rs6957529C were associated with higher viral loads during the early chronic phase of 
infection (fig. 4.2.2.3D). Interestingly, the rs1154330G was significantly associated with lower 
CD4+ T cell counts and higher viral loads during both the acute phase and the early chronic 
phase of infection in the CAPRISA AI 002 cohort (fig. 4.2.2.3). This observation was 
consistent with the observation that the rs1154330G was significantly associated with 
increased susceptibility. However, rs8043 was neither association with CD4+ T cell counts 









Figure 4.2.2.3. Effect of TNP03 polymorphism on CD4+ T cells and viral load in primary HIV-
1 infected black South Africans (n =52). A and B, association of individual TNPO3 SNP with 
differential CD4+ T cell counts and viral loads, respectively, during the acute phase of 
infection. C and D, association of individual TNPO3 SNP with differential CD4+ T cell counts 
and viral loads, respectively, during the early chronic phase of infection (refer to Table 4.2.2.1 
for corresponding rs number for the SNP number). 
 
Next, we tested the effect of each SNP on the rate of CD4+ T cell decline in the CAPRISA 
cohort using Cox model. However, no association was observed between the SNPs and the 
rate of CD4+ T cell decline in the CAPRISA AI 002 cohort. Lack of association between 
TNPO3 genetic variation and the rate of CD4+ T cell decline could be attributed to a small 
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number of participants in the CAPRISA AI 002 cohort. For example, there were only 13 SPs 
who carried the rs1154330G.  
 
4.2.2.4 Effect of the SNP rs1154330 of TNPO3 on CD4+ T cell decline in the Sinikithemba 
Cohort 
The results obtained from the CAPRISA AI 002 cohort suggested that the rs1154330G may 
be associated with higher susceptibility to HIV-1 infection, lower CD4+ T cell counts post 
infection and higher viral loads. However, the effect of the rs1154330G on the CD4 decline 
was not pronounced probably due to fewer (n=13) SPs containing the rs1154330G in the 
CAPRISA AI 002 cohort. We therefore extended the rs1154330G analysis to the larger 
Sinikithemba cohort comprising 450 HIV-1 chronically infected participants–within the same 
geographical area–in order to elucidate the effect of the rs1154330G on the rate of CD4+ T 
cell decline. Since the Sinikithemba cohort is a seroprevalent cohort with unknown dates of 
infection, the effect of the rs1154330G was examined at baseline for CD4+ T cell levels and 
on the trajectory of CD4+ T cell decline over 5 years of follow-up. There was no association 
observed between the rs1154330G and CD4+ T cell counts at baseline (fig. 4.2.2.4 A), 
probably due to the fact that participants enrolled into this study cohort were at different 








Figure 4.2.2.4. Rates of CD4+ T cell decline stratified by TNPO3 SNP rs1154330. A, 
influence of SNP rs1154330 on CD4+ T cell counts at baseline; B, CD4+ T decline in 
individuals carrying the wild type genotype (AA) for SNP rs1154330 are represented by a 
black curve whereas CD4+ T decline in participants carrying the mutant genotype (AG) are 
represented by a red curve.  
 
Interestingly, the rs1154330G was significantly associated with a faster rate of CD4+ T cell 
decline in the Sinikithemba cohort (p<0.01) (fig. 4.2.2.4B). These results confirmed that the 
rs1154330G may be associated with enhanced HIV-1 replication in vivo as evident from 
increased susceptibility to HIV-1 infection, higher levels of HIV-1 loads and lower levels of 
CD4+T cell count post infection in the CAPRISA AI 002 cohort (sections 4.2.2.2 and 4.2.2.3).  
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4.2.3 Discussion and Conclusions 
Interestingly, the SNP rs1154330G was associated with increased susceptibility to HIV-1 
infection as was reflected by faster acquisition of HIV-1 infection by individuals who harbored 
the rs1154330G. The rs1154330G was further associated with lower CD4+ T cell counts and 
higher viral loads during primary infection in the CAPRISA AI 002 cohort. Lastly, the 
rs1154330G correlated significantly with rapid disease progression, as was reflected by the 
faster rate of CD4+ T cell decline in in individuals carrying the rs1154330G in the 
Sinikithemba cohort. These results corroborate the role of TRN-SR2 as an important cellular 
cofactor for HIV-1 replication as previously established through in vitro studies [32, 67, 160].  
 
In this study, we have investigated the association of genetic variation in the TNPO3 gene 
with susceptibility to HIV-1 infection and disease progression in HIV-1 longitudinal South 
African cohorts. The rs1154330G, which is in intron 12 of TNPO3, was associated with 
increased susceptibility to HIV-1 infection and disease progression in the South African 
cohorts. These findings suggest that the rs1154330G gives HIV-1 selective advantage for 
infection and enhanced replication in vivo. In addition to the SNP rs1154330, 5 other SNPs 
also in the intron regions and 2 SNPs in the exon region were also studied in the CAPRISA 
AI cohort.  
 
The rs2305325A was associated with higher CD4+ T cell count and lower viral load during 
acute phase of infection. The rs2305325A was not associated with viral load during early 
chronic phase of infection. The rs35060568A was associated with higher viral load during 
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both the acute phase and the early chronic phase infection. However, the association 
between the rs35060568A and CD4+ T cell counts was only observed during the early 
chronic phase of infection. 
 
The rs6957529C showed inconsistent effect on CD4+ T cell count and viral load between the 
acute and early chronic phase of infection. The rs6957529C was associated with higher 
CD4+ T cell counts and lower viral loads during the acute phase of infection whereas the 
opposite effect was observed during early chronic phase of infection. The plausible 
explanation for this could be that the virus adapts differently to be able to replicate more 
effectively during the later stages of HIV-1 infection [202]. The rs10229001C was associated 
with higher CD4+ T cell counts and lower viral loads during the early chronic phase of 
infection only. 
 
The analysis of the SNP rs1154330 was extended to a larger Sinikithemba cohort of 450 
chronically infected individuals on the basis that this was the only SNP that showed 
consistent results in the CAPRISA AI 002 cohort. In the Sinikithemba cohort, the rs1154330G 
could only be examined at baseline for its effect on CD4+ T cell counts and viral loads since 
the date of infection was not known for participants in this cohort. The effect of the 
rs1154330G could also be assessed on the rate of CD4+ T cell decline in this cohort. 
Interestingly, the rs1154330G was significantly associated with rapid CD4+ T cell decline in 
the individuals harboring this allele. Since the rs1154330G is in the intron 12 region, 
therefore it probably exerted its effect by affecting the mRNA expression profile of the TRN-
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SR2. However, the rs1154330G was neither associated with CD4+ T cell count nor viral load 
at baseline. Lack of association could be explained by the fact that individuals in the 
Sinikithemba cohort were enrolled into the study while they were at different stages of HIV-1 
disease.  
 
This study had two major limitations: (1) the CAPRISA AI cohort, the only cohort with known 
dates of infection had few HIV-1 infected individuals and; (2) the date of infection was not 
known for HIV-1 chronically infected individuals, and therefore the clinical data of these 
individuals could not to be categorized and analyzed according to the different phases of 
HIV-1 infection.  
 
Results obtained in this study demonstrated that the rs1154330G was significantly 
associated with increased susceptibility to HIV-1 infection. This allele was also associated 
with higher levels of viral loads and lower levels of CD4+ T cell counts during primary 
infection and was further associated with rapid disease progression as was reflected by rapid 
CD4+ T cell decline. This study has to be replicated in a larger cohort of HIV-1 infected 
individuals whose date of infection is known in order to elucidate the role of the genetic 
variation inTNPO3 gene during the course of HIV-1 infection. 
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4.3 Association of Polymorphisms in the LEDGF/p75 Gene (PSIP1) with Susceptibility 
to HIV-1 Infection and Disease Progression 
HIV-1 requires host cell factors to successfully complete its replication cycle [289]. Lens 
epithelium derived growth factor p75 (LEDGF/p75) also known as proprotein convertase 4 
(PC4) or splicing factor, arginine/serine-rich 1 (SFRS1) interacting protein 1 (PSIP1), is a 
ubiquitous protein expressed in a wide range of tissues and cell types at all stages of 
development (by convention, the protein is referred to as LEDGF/p75 and the gene named 
PSIP1). LEDGF/p75 is known for its involvement in HIV integration and its important role in 
promoting HIV-1 replication in vitro [171, 179]. LEDGF/p75 is a member of the hepatoma-
derived growth factor (HDGF) family, members of which are involved in chromosomal 
replication, transcription and chromatin structure formation [174-176, 178-180, 183].  
 
LEDGF/p75 has been shown to interact with HIV-1 integrase (IN) through specific binding 
that occurs between the integrase binding domain (IBD) of LEDGF/p75 and the catalytic core 
domain of HIV-1 IN to mediate the nuclear accumulation of IN and to target HIV-1 integration 
into active transcription unit sites [187, 188, 201, 202, 290, 291]. Disruption of the interaction 
between LEDGF/p75 and HIV-1 IN, either by HIV-1 IN mutations or by LEDGF/p75 
knockdown, leads to an inhibition of HIV-1 replication [177, 189, 292]. The data presented 
above from intensive in vitro studies have convincingly demonstrated that LEDGF/p75 is an 




Studies of the influence of human genetic variation on susceptibility to HIV-1 infection and 
disease progression may reveal the essential in vivo host factors that interact with HIV-1 and 
their epidemiologic importance at the population level [73]. Although this approach has 
previously been used to identify HIV/AIDS modifying variants in human genes, the majority of 
these studies have been conducted using populations mainly from developed countries [73, 
75, 286, 293]. However, it has been clearly demonstrated that there are considerable 
differences in allele frequencies among potential disease influencing genes between ethnic 
groups and geographically separated populations [107]. There is therefore a pressing need 
to extend host genetic studies of HIV-1 infection to developing world populations heavily 
burdened with HIV/AIDS and to factors that are possible targets for therapeutic or other 
plausible biomedical interventions. Although LEDGF/p75 has been demonstrated to be 
essential for HIV-1 integration in vitro, there was no data published on the influence of 
genetic variation in PSIP1 on HIV-1 disease outcome. In this study, we therefore investigated 
the influence of genetic variation in PSIP1 on HIV-1 infection and disease progression in 
South Africans cohorts.  
 
4.3.1 Materials and Methods 
Study participants. The Center for the AIDS Programme of Research in South Africa Acute 
Infection 002 (CAPRISA AI 002) [268, 269] and the Sinikithemba [270, 271] cohorts were 
used for this study (see section 3.1 for more details). Ethical approval for this study was 
obtained from the University of KwaZulu-Natal‟s Biomedical Research Ethics Committee. All 




4.3.1.1 Identification of polymorphisms in the C terminal region of PSIP1 
Single nucleotide polymorphisms (SNPs) in the C terminal region of PSIP1 were screened in 
a panel of 83 seronegative (SN) and 43 seropositive (SP) black South African women from 
the CAPRISA AI 002 cohort by resequencing part of the C-terminal region of the PSIP1 
gene. PSIP1 encodes two proteins by alternative splicing, LEDGF/p75 and p52 that have a 
high degree of homology but p52 lacks the C-terminus region of LEDGF/p75. Sequence 
comparison and BLAST search were performed to select LEDGF/p75-specific PCR primers. 
A 50 µl PCR reaction mixture containing 1X PCR buffer, 3.5 mmol MgCl2, 0.25 mmol dNTP 
mix, 0.25 U/µl Expand Taq polymerase, 0.4 ρmol/µl of forward (LEDGFDNA1) and reverse 
(Seq 5) primer and 100 ng DNA was prepared (Table 4.3.1.1). 
 
This was amplified at 95 ºC for 10 minutes, 35 cycles of 94 ºC for 30 seconds, 60 ºC for 30 
seconds, 72 ºC for 45 seconds, and a final 10 minute extension step at 72 ºC. The PCR 
product was purified using Qiagen PCR Purification Kit (Qiagen) and sequenced using 
overlapping primers to cover a 1,679 bp long DNA fragment of the C-terminal region of 
PSIP1 (starting from 1,190 bp upstream of exon 10 to 105 bp downstream of exon 13), this 
region included the IBD  (Table 4.3.1.1). BigDye Terminator Kit (Applied Biosystems, Foster 





Table 4.3.1.1. PCR, sequencing and real time RT-PCR primers and cycling conditions used 










PCR Primer Sequence  5’3’ 
 
 





F: TGG GCT CAA AGC ATTA ATC C 
R: TCT GTG GCG TAT ACA CAG TG 








F: GCC AGA TATGAT TTA ATC TAG 
R: GTA GAC TTT TCC  ATG ATT CCT GAC 
 
F: GCC TGT ATA TAG AAA TAC TGG 
R: TCT GTG GCG TAT ACA CAG TG 
 
F: CTT CAA AGG ATA CAT GC 

















G  A 
 
 
G  C 
 
 
T  C 
 
 
A  G 
 
 























F: GTC AAC CCC ACC GTG TTC TTC 





F: AAG GTC GGA GTC AAC GGA TT 
R: CTC CTG GAA GAT GGT GAT GG 
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4.3.1.2 Genotyping of SNPs in PSIP1 from the CAPRISA AI 002 Participants 
The rs numbers instead of the SNP numbers will be used below, please refer to the table 
above (Table 4.3.1.1) to find the corresponding SNP numbers for rs numbers. The four 
intronic ht SNPs rs2277191, rs1033056, rs10283923 and rs12339417 available from NCBI 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP) and HapMap databases (http://www.hapmap.org) 
were selected by considering location, spacing, and allele frequency of at least 10%. The 
exonic SNP rs61744944 (Q472L) also available from the aforementioned databases (fig. 
4.3.1.2, and Table 4.3.1.1) was selected based on its association with clinical outcome in the  
preliminary analysis (see section 4.3.21). Therefore all 5 SNPs were genotyped in 247 
patient samples (195 SNs and 52 SPs) from the CAPRISA AI 002 cohort.  
 
The intronic ht SNPs were chosen because they are tag SNPs for the PSIP1 in the Yoruba 
from Nigeria (http://www.snp.cshl.org) and SNP rs61744944 based on the preliminary 
analysis of the sequencing data that suggested an association between the minor allele (T) 
of SNP rs61744944 (rs61744944T) with increased susceptibility to HIV-1 infection, lower 
CD4+ T cell counts post HIV-1 infection and higher viral loads. Genotyping was performed by 
TaqMan SNP assay as per manufacturer‟s protocol (Applied Biosystems). TaqMan assays 
were obtained from the Assay-by-Demand service of Applied Biosystems 
(http://www.appliedbiosystems.com). Eight negative water controls were included in each run 
to rule out PCR contamination. Samples were genotyped in duplicate and genotypes were 




4.3.1.3 Genotyping of SNPs in PSIP1 from the Sinikithemba Participants 
Analysis of the PSIP1 polymorphisms in the CAPRISA AI 002 cohort showed an association 
between some SNPs in PSIP1 and HIV-1 outcomes. We therefore extended the analyses to 
a larger cohort of 450 SPs from Sinikithemba cohort, to either confirm or refute the results 
obtained from the CAPRISA AI 002. Genotyping assays were performed as described above. 
 
4.3.1.4 LEDGF/p75 mRNA expression Analysis 
Peripheral blood mononuclear cells (PBMCs) from 57 HIV-1-negative participants and 38 
recently infected participants from the CAPRISA AI 002 cohort were isolated and LEDGF/p75 
expression levels were measured by quantitative RT-PCR. RNA was extracted from 2 x 106 
PBMCs immediately after thawing using Trizol LS reagent (Invitrogen, Carlsbad, California, 
USA) according to the manufacturer‟s protocol. RNA was reverse transcribed using the 
iScript complementary DNA (cDNA) synthesis kit (Bio-Rad). LEDGF/p75 mRNA expression 
was quantified by quantitative TR-PCR using SYBR Green Chemistry on a Roche 
LightCycler version 1.5 (Roche Diagnostics). LEDGF/p75 cDNA was amplified using primers 
(Table 4.3.1.1) designed to uniquely amplify the IBD of PSIP1 (GeneBank accession no. 
NM_021144). Each PCR reaction contained 3 mmol/µl MgCl2, 0.5 ρmol/ml of each primer, 1 
X LightCycler FastStart DNA Master SYBR Green I (Roche), 1 µg of cDNA, and water added 
to 10 µl final volume. Reactions were run in duplicate. The PCR conditions were: 1 cycle at 




Standard curves were generated using 10-fold serial dilutions of cDNA of known 
concentration. Samples and standards were run in duplicates and average values were used 
to compute gene copy number. The housekeeping gene, glyceraldehyde 3-diphosphate 
dehydrogenase (GAPDH) (NM_002046), was used to normalize for variations in cell count or 
differences in nucleic acid extraction as previously described [250]. Relative mRNA levels of 
LEDGF/p75 to GAPDH were calculated for each sample by dividing the concentration of 
LEDGF/p75 by the concentration of GAPDH. 
 
4.3.1.5 Expression and purification of recombinant proteins 
His6-tagged HIV-1 integrase, 3X flag-tagged LEDGF/p75, MBP-JPO2 and MBP-pogZ were 
purified for AlphaScreen applications as described previously [258, 259].  
 
4.3.1.6 AlphaScreen 
The concentration units of the reagents used from this section onwards would be written as 
they appear in the article that was published from this work. 
  
The AlphaScreen assay is a technique used to measure protein-protein affinity interactions. 
To measure the influence of the SNP rs61744944 (Q472L) on the binding affinity of 
LEDGF/p75 we performed AlphaScreen assay according to the manufacturer's protocol 
(Perkin Elmer, Benelux). Reactions were performed in 25 μl volume in 384-well Optiwell™ 
microtiter plates (Perkin Elmer). The reaction buffer contained 25 mM Tris–HCl (pH 7.4), 
150 mM NaCl, 1 mM MgCl2, 0.01% (v/v) Tween-20 and 0.1% (w/v) bovine serum albumin. 
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300nM His6-tagged IN was incubated with 100 nM flag-LEDGF/p75 for an hour at 4°C. 
Subsequently 5 µl of Ni-chelate–coated acceptor beads and 5 µl anti-flag donor beads were 
added to a final concentration of 20 µg/ml of both beads. Proteins and beads were incubated 
for 1 hour at 30 ºC. Exposure of the reaction to direct light was avoided and the emission of 
light from the acceptor beads was measured in the EnVision plate reader (Perkin Elmer, 
Benelux) and analyzed using the EnVision manager software. Assays with JPO2 or pogZ, 
respectively, were essentially performed as described previously [294, 295].  
 
4.3.1.7 Complemented cell lines 
Complemented HeLaP4/CCR5 knockdown cells (A3 clone) were generated and grown as 
described earlier [173]. Briefly, the Q472L mutation was introduced in pLNC_LEDGF BC-
Ires-Bsd and MLV-based vectors were generated [204]. Following transduction, cells were 
selected with 3 µg/ml blasticidin (Invitrogen, Merelbeke, Belgium). Protein expression was 
verified by Western blot analysis and immunocytochemistry (data not shown). 
 
4.3.1.8 Virus strains 
The molecular clone pNL4.3 was obtained through the NIH AIDS Research and Reference 
Reagent Program. Virus stock (HIVNL4.3) was produced as described earlier [204].  
 
4.3.1.9 HIV-1 breakthrough assay 
Cells were seeded at 30,000 cells per well in a 6-well dish and infected as described earlier 
with minor modifications [296]. Briefly, cells were infected with 56,000 pg p24 HIVNL4.3 in a 
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total volume of 2 ml (MOI 0.01). 24 hrs later, cells were washed twice with 1X PBS prior to 
addition of 4 ml of fresh medium. HIV replication was monitored by sampling the culture 
medium for p24 ELISA (HIV-1 p24 ELISA kit, Perkin Elmer).  
 
4.3.1.10 Quantitative PCR 
Integrated proviral copies were quantified by real-time quantitative PCR (Q-PCR) on genomic 
DNA using the iQ5 Multicolor RT PCR detection system (BioRad, Nazareth, Belgium). In 
order to allow quantification of integrated proviral copies in HIV-1NL4.3 infected cells, cells 
were subcultured at day 6 and grown under azidothymidine/ritonavir treatment for 10 days, 
0.5µM and 1.5µM, respectively, i.e. 25-fold IC50 as determined in MT4/MTT assay [297] to 
eliminate all non-integrated viral DNA. Genomic DNA was extracted using the GenElute 
mammalian genomic DNA miniprep kit (Sigma, Bornem, Belgium); for each reaction 100 ng 
was used for Q-PCR. Integrated copies for HIV-1NL4.3 were quantified using a Gag-derived 
primer-probe set. Each 25 µl reaction contained 12.5 µl 2x iQ Supermix (Biorad), 40 nM 
primer and 40 nM probe. RNaseP was used as house-keeping gene control (TaqMan 
RNaseP control reagent, Applied Biosystems, the Netherlands). All samples were run in 
quadruplet and subjected to 3 min at 95°C, 50 cycles of 95°C for 10s and 55°C for 30 s. Data 
were analyzed with iQ5 Optical System software (BioRad, Nazareth, Belgium). 
 
4.3.1.11 Statistical Analysis 
The difference in allele frequency distribution between the HIV-1-positive and HIV-1-negative 
group was determined by Fisher‟s exact test (FET) for each SNP to test the null hypothesis 
that allele frequencies were the same in the two groups. The effect of each SNP on HIV-1 
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viral load and CD4+ T cell count was determined using a Generalized Estimating Equation 
(GEE) model [277] taking into account longitudinal measures for each participant. Viral loads 
were log-transformed and the square root of CD4+ T cell count was used to normalize their 
measurements.  
 
Kaplan-Meier survival statistics and the Cox proportional hazards model (Cox model) were 
used to assess the effect of each SNP on time to HIV-1 acquisition after enrollment and on 
the rate of progression to AIDS defined as CD4+ T cell decline to less than 350 cells/μl 
(CD4<350). Decline in CD4 levels was determined and compared for the group with one or 
two copies of the minor allele to a reference group with two copies of the major allele 
(dominant genetic model), for each SNP. The significance of genotypic associations and 
relative hazard (RH) was determined by unadjusted Cox regression analysis for the dominant 
genetic model.  
 
LEDGF/p75 mRNA expression levels were compared between SNs and SPs by performing 
dot plot graphical representation, nonparametric statistical analysis, and correlation 
(Pearson). Values were expressed as median values. Differences between the 2 groups 
were evaluated using Dunn‟s multiple comparison test, whereas the Mann-Whitney U test 
was used for any 2-group comparisons. The software used for the analysis was SAS version 





4.3.2.1 Study design and selection of patient samples 
Two hundred and forty seven samples (52 SPs and 195 SNs) from the CAPRISA AI 002 
cohort and 403 samples from the Sinikithemba cohort were available for genotyping analysis. 
32 samples from the CAPRISA AI cohort (10 SPs and 22 SNs) and 37 SPs from the 
Sinikithemba cohort were excluded from all analysis due to sample unavailability or poor 
quality genotype data.  
 
4.3.2.2 Identification of Q472L as an exonic polymorphism in the C-terminus of LEDGF/p75  
The PSIP1 gene is approximately 47kb in length; consisting of fifteen exons (fig. 4.3.2.3.1). 
Therefore LEDGF/p75-specific primers were used to re-sequence a fragment (1.679kb long) 
of the C-terminus region of PSIP1 in 43 SPs and 83 SNPs individuals from the CAPRISA AI 
002 cohort (fig. 4.3.2.2). Resequencing of this fragment which included the IBD was 
conducted in order to screen for novel SNPs within this region that might be associated with 











Figure 4.3.2.2. C-terminus fragment of the PSIP1 gene that was re-sequenced to identify 
novel polymorphism that might be associated with the attenuated HIV-1 infection. 
 
Fourteen previously described SNPs (dbSNP, www.ncbi.nlm.nih.gov) were discovered in the 
PSIP1 gene by resequencing part of the C-terminal region of the PSIP1 gene. Only one SNP 
rs61744944; a nonsynonymous SNP which result in amino acid change Glutamine to 
Leucine at position 472 (Q472L) of the LEDGF/p75 protein, was located in the exon region 
(exon 13) and the remaining SNPs were in the intron regions. Fisher‟s exact test was used to 






Table 4.3.2.2. Fourteen SNPs identified by resequencing and their association with 















rs112104292 5/126 0.18 
A 41250A/C 
(Intron) 
rs4741508 60/126 0.25 
G 41582G/A 
(Intron) 
rs909323 1/126 1.00 
C 41841C/A 
(Intron) 
rs73421380 3/126 1.00 
C 41857G/A 
(intron) 
rs80047054 2/126 1.00 
G 41994C/A 
(Intron) 
rs12684386 7/126 1.00 
A 42433A/T 
(Intron) 








rs34331255 1/126 1.00 
T 42732A/T 
(Intron) 
rs34331255 1/126 0.33 
C 42819C/T 
(Intron) 
rs2795124 2/126 1.00 
C 44950C/T 
(Intron) 
rs1046388 3/126 0.55 
TTTGG 45201_45205_Del 
(Intron) 
rs4741507 1/126 1.00 
A 42350A/T (Q472L)  
(exon) 
rs61744944 23/126 0.04 
 
The rs61744944T was significantly associated with increased susceptibility to HIV-1 infection 
(Table 4.3.2.2). Kaplan-Meier survival analysis presented a clear separation of curves 
stratified for the major allele (A) of rs61744944 (represented by a blue curve) and the 
rs61744944T (represented by a black doted curve) on susceptibility to HIV-1 infection in 
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black South Africans (RH = 2.8, 95% CI = 1.6 – 7.3; uncorrected p = 0.04, Cox model) (fig. 
4.3.2.2.1).  
 
Figure 4.3.2.2.1. Kaplan-Meier survival curve analysis of A42350T (SNP5) on susceptibility 
to HIV-1 infection in black South Africans. 
 
Subsequently, all 14 SNPs were tested for association with CD4+ T cell counts and viral 
loads post HIV-1 infection. The rs61744944T was further found to be significantly associated 
with higher CD4+ T cell count (p < 0.01) and lower viral loads (p < 0.01) over a period of 24 




Figure 4.3.2.2.2. The influence of exonic SNP (rs61744944) on HIV-1 clinical outcomes. A, 
the association between viral loads and the SNP rs61744944; B, the association between 
CD4+ T cell counts and the rs61744944 SNP. WT represent the wild type genotype (AA) and 
MUT represent mutant genotype (AT) of the exonic SNP.  
 
The exonic SNP rs61744944 showed consistent and significant association with disease 
outcome. However, there was an unusual phenomenon with the results obtained from the 
preliminary analysis where the rs61744944T was associated with increased susceptibility to 
HIV-1 infection and yet higher CD4+ T cell counts and lower viral loads post infection. This 
could also be attributed to the fact that pathophysiologic factors associated with foundational 




4.3.2.3 Effect of PSIP1 SNPs on Susceptibility to HIV-1 Infection in the CAPRISA AI cohort. 
The analysis of the preliminary data (section 4.3.2.2) suggested that genetic variation within 
the PSIP1 gene might be associated with clinical outcomes in black South Africans. The 
analysis of PSIP1 genetic variation was therefore extended to more participants (n=247) from 
the CAPRISA AI 002 cohort. 4 haplotype ht SNPs of the PSIP1 gene and the exonic SNP 
rs61744944 (Q472L) were selected (see section 4.3.2.2) to genotype 247 participants from 
CAPRISA AI 002 cohort (fig. 4.3.2.3.1). The intronic ht SNPs were selected because they are 
in linkage disequilibrium with other SNPs within the PSIP1 gene and therefore they would 
give the overall effect of genetic variation of the PSIP1 gene on HIV-1 disease outcome. 
 
CAPRISA AI 002 cohort comprises high risk individuals who were initially identified as HIV-1 
negative and then followed longitudinally. This study design allowed us to test whether 
genetic variation in PSIP1 was associated with susceptibility to HIV-1 infection. The minor 
allele frequencies (MAF) of SNPs and haplotype frequencies are shown at the bottom and 











Figure 4.3.2.3.1. PSIP1 gene: coding exons are marked with solid blue boxes. Minor allele 
frequencies (MAF) of the SNPs are shown for the CAPRISA and Sinikithemba (SK) cohorts 
at the bottom of panel. Hap is the acronym used for haplotype. 
 
The minor allele (A) of rs2277191 (rs2277191A) was more frequent (25%) among the SPs in 
comparison to the SNs (p=0.06) (fig. 4.3.2.3.2A), suggesting that there could be an 









Figure 4.3.2.3.2. Association of the rs2277191A with susceptibility to HIV-1 infection. A, 
frequency distribution of the rs2277191A between HIV-1 negative and positive groups; B, 
Kaplan-Meier survival curve showing a clear separation of curves, GG wild type genotype 
(represented by black curve) and AG/GG mutant genotypes (represented by red curve) of the 
SNP rs2277191. 
 
Kaplan-Meier survival analysis of time to HIV-1 acquisition suggested a trend of association 
between the rs2277191A and HIV-1 acquisition (RH = 2.21, 95% CI = 0.92–5.28; 







Table 4.3.2.3. Association of PSIP1 SNPs with HIV-1 Acquisition in the CAPRISA AI 002 






22 and 12 versus11 (reference group)* 
        RH (95% CI)               P - value 
rs2277191  
(SNP1) 
    GG    AG  AA   
SN 195 164(0.84) 26(0.13) 5 (0.03)   
SP 52 39 (0.75) 12(0.23) 1 (0.01)    2.21 (0.92 – 5.28)           0.08 
rs10283923 
(SNP2) 
    GG    CG  CC   
SN 195 80 (0.41) 77(0.39) 38(0.20)   
SP 52 20 (0.38) 23(0.44) 9 (0.17)   0.99 (0.44 – 2.24)            0.98 
rs12339417 
(SNP3)  
    TT    CT  CC   
SN 195 99 (0.51) 70(0.36) 26(0.13)   
SP 52 29 (0.56) 19(0.36) 4 (0.08)   0.60 (0.26 – 1.37) 0.23 
rs1033056 
(SNP4) 
    AA    AG  GG   
SN 195 121(0.62) 60(0.31) 14(0.07)   
SP 52 35 (0.67) 16(0.31) 1 (0.02)   0.85 (0.36 – 2.01) 0.71 
rs61744944 
(SNP5) 
    AA     AT  TT   
SN 195 168(0.86) 24(0.12) 3(0.02)   
SP 52 41 (0.79) 10(0.19)  1 (0.02)   1.90 (0.71 – 5.09)  0.20 
Kaplan-Meier survival statistics and the Cox proportional hazards model (Cox model) were 
used to assess the effect of each SNP on time to HIV-1 acquisition. P-values uncorrected for 
multiple comparisons are shown. *11 represent the wildtype genotype, 12 represent 
heterozygous genotype and 22 represent homozygous genotype. 
 
Although the rs61744944T was associated with increased susceptibility to HIV-1 infection in 
the preliminary data analysis of 126 participants, it lost its association when 247 participants 
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were analyzed. In this larger group of 247 participants only the rs2277191A showed a trend 
towards association with higher likelihood of acquiring HIV-1 infection (Table 4.3.2.3). 
 
4.3.2.4 Effect of the PSIP1 SNPs on CD4+ T cell counts and viral loads in the CAPRISA AI 
002 Cohort 
The approximate time of infection was known for HIV-1 infected participants in the CAPRISA 
AI 002 cohort. Since CD4+ T cell counts and viral loads can fluctuate significantly during HIV-
1 primary infection, we analyzed the data in two specific intervals, 0-3 months post infection 
(acute phase of infection) and 3-12 months post infection (early chronic phase of infection) in 








Figure 4.3.2.4. Association between the individual SNPs of the PSIP1 gene and clinical 
outcomes reflected by square root CD4+ T cells and log viral loads during acute phase of 
infection (A and B) and during early chronic phase of infection (C and D). SNP1, SNP2, 
SNP3, SNP4 and SNP5 refer to rs2277191, rs10283923, rs12339417, rs1033056 and 
rs61744944, respectively. 
 
After correction for multiple comparison, dominant model analysis using GEE showed that 
the minor allele (A) of rs1033056 and the rs61744944T were significantly associated with 
lower CD4+ T cells (p < 0.01) and viral load (p = 0.01), respectively, during the acute phase 
of infection (fig. 4.3.2.4A and B). The rs2277191A was associated with lower CD4+ T cell 
count (p < 0.01) while the minor allele (C) of rs12339417 (rs12339417C) was associated with 
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higher CD4+ T cell counts (p < 0.01) during early chronic phase of infection (fig. 4.3.2.4C). 
The minor alleles of all SNPs except rs61744944 were significantly associated with lower 
viral loads (p < 0.01) during the early chronic phase of infection (fig. 4.3.2.4D).  
 
4.3.2.5 Effect of PSIP1 SNPs and Haplotypes on CD4+ T cell decline in the CAPRISA AI 002 
Cohort 
Few studies have analyzed the association of genetic factors with the rate of CD4 decline 
particularly in an African HIV-1 cohort with known time of infection.  
 






SNPs on AIDS 
Progression 
RH      95%  CI         P 
Haplotype 
Number 
Haplotypes on AIDS 
Progression 
RH        95%  CI        P 
CD4 < 350 SNP1 5.98 2.27 – 5.82 0.04 HAP1 1.84 0.55- 6.12 0.77 
CD4 < 350 SNP2 2.68 0.99 – 7.24 0.70 HAP2 0.84 0.19-3.77 0.21 
CD4 < 350       SNP3 1.25 0.44 - 3.56    0.29 HAP3 0.00 0.00-0.00 0.99 
CD4 < 350 SNP4 2.05 0.70 - 6.02 0.90 HAP4 5.41 1.92 -5.24 0.09 
CD5 < 350 SNP5 1.74 0.50 – 6.05                                                                                         0.71 HAP5 1.58 0.36 -7.49 0.66
Cox proportional hazards model (Cox model) was used to calculate the rate of CD4 decline 
to less than 350 cells/ml. P-values uncorrected for multiple comparisons are shown. SNP1, 






We therefore tested the effect of the PSIP1 SNPs on the rate of CD4+ T cell decline. The 
rs2277191A showed a weak but significant association with rapid CD4+ T cell decline (p = 
0.04, Cox model) (Table 4.3.2.5). Haplotype 4 (HAP4), the only haplotype carrying the 
rs2277191A, showed a trend of association with rapid CD4+ T cell decline to CD4<350 (RH = 
5.41, 95% CI =1.92-15.24, p = 0.09) (Table 4.3.2.5). None of the other SNP genotypes 
showed differences in the rate of CD4+ T cell decline.  
 
4.3.2.6 Effect of PSIP1 SNPs in the Sinikithemba Cohort with Chronic HIV Infection 
The results from the CAPRISA AI 002 cohort suggested that genetic variation in PSIP1 gene 
may be associated with differential disease outcome. However, interpretation of these data 
was complicated by the small sample size (52 SPs) of the study cohort and the fluctuations in 
CD4+ T cell counts and viral loads experienced during primary infection. We therefore 
extended our analysis to a larger cohort (Sinikithemba cohort), from within the same 
geographical area, in order to elucidate the role of the PSIP1 genetic variants in HIV-1 
pathogenesis.  
 
Two SNPs, rs10283923 and rs1033056, were excluded from this analysis because they 
showed no association with CD4+ T cell counts during early chronic phase of infection in the 
CAPRISA AI 002 cohort. The rs61744944 was included in this analysis based on the 
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preliminary data where it showed consistent association with both CD4+ T cell counts and 
viral loads over 24 months post infection. The Sinikithemba cohort is a seroprevalent cohort 
with unknown dates of infection. Therefore, the effects of the SNPs rs2277191, rs12339417 




Figure 4.3.2.6. Rates of CD4+ T cells declinestratified by genotypes for A- rs2277191, B- 
rs12339417, and C- 61744944 for the Sinikithemba seroprevalent cohort. 
 
The influence of each of the three SNPs on disease progression was assessed by comparing 
the slopes of CD4+ T cell levels for each of the three SNPs using the dominant model. The 
SNP rs2277191 did not show any association with disease progression in the Sinikithemba 
cohort. Interestingly, the rs12339417C was associated with delayed disease progression as 
was reflected by a slower rate of CD4+ T cells decline to CD4<350 (p = 0.02, Cox model) 
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(Figure 4.3.2.6B). The SNP rs61744944 was also not associated with HIV-1 disease 
outcome in the Sinikithemba cohort. 
 
4.3.2.7 LEDGF/p75mRNA expression levels 
Next we studied the association between the PSIP1 genetic variation and expression mRNA 
levels of LEDGF/p75. To this end, we performed quantitative RT-PCR on LEDGF/p75 mRNA 
levels in 57 HIV-1 negative and 38 recently infected participants from the CAPRISA AI 002 
cohort. For 13 of the recently infected participants, samples pre- (at study entry) and post-
HIV-1 infection were available for analysis. 
 
Figure 4.3.2.7. A, Expression of LEDGF/p75 mRNA in PBMCs obtained from HIV-1 positive 
versus negative participants. B, Expression of LEDGF/p75 mRNA in PBMCs obtained 
seroconverters versus nonseroconverters. C, Expression of LEDGF/p75 mRNA as 
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modulated by different genotypes of the SNP rs12339417. The TTwild type genotype of 
SNP rs12339417, CTheterozygous genotype of SNP rs12339417, the horizontal line in the 
middle of the points denotes the median value.  
 
LEDGF/p75 mRNA expression data indicate that HIV-1 negative group express higher 
LEDGF/p75 mRNA levels compared to the HIV-1 positive group (p = 0.02) (fig. 4.3.2.7A). In 
order to ascertain whether LEDGF/p75 expression levels are dysregulated by HIV-1, 13 
samples matched (pre- and post-HIV-1) samples were analyzed. There was higher 
LEDGF/p75 mRNA expression levels in PBMC at baseline (preinfection) from seroconverters 
as compared to PBMC obtained from non-seroconverters (p < 0.01) (fig. 4.3.2.7B). These 
results suggest that higher levels of LEDGF/p75 mRNA expression may be associated with a 
higher likelihood of acquiring HIV-1 infection and they also indicate that LEDGF/p75 mRNA 
expression levels are dysregulated by HIV-1 infection.  
 
Lastly, we studied the association between PSIP1 genetic variation and differential 
expression of LEDGF/p75 mRNA in the seronegative group. Results obtained from this 
analysis indicate that the differential expression of LEDGF/p75 mRNA was influenced by the 
SNP rs12339417. The rs12339417C was associated with reduced levels of LEDGF/p75 
mRNA expression (p < 0.01) (fig. 4.3.2.7C). Interestingly, the expression data is consistent 
with the SNP rs12339417 genotype data where the rs12339417C was associated with higher 
CD4+ T cell counts, lower viral loads and slower rate of CD4+ T cell decline (section 4.3.2.4 




4.3.2.8 Functional analysis of Q472L LEDGF/p75 
To determine the impact of the Q472L mutation on the interaction of LEDGF/p75 with IN we 
measured its affinity in an AlphaScreen assay (Table 4.3.2.8) and evaluated the effect of the 
Q472L mutation on the interaction with JPO2 and pogZ, two cellular binding partners of 
LEDGF/p75 [258, 259]. While the affinity for JPO2 and pogZ was identical for the wild-type 
and the mutant protein, an almost 2-fold decrease in the Kd value for the Q472L mutant was 
observed (Table 4.3.2.8), suggesting stronger binding of the latter to HIV-1 IN. 
 





1Kd for interaction of LEDGF/p75 WT or Q472L with indicated recombinant proteins as 
measured by AlphaScreen. Average values ± SD for two independent measurements in 
triplicate. 
 
Next, we evaluated the Q472L mutant in cell culture. Potent RNAi-mediated knockdown of 
LEDGF/p75 severely hampers HIV replication affecting the integration step of the provirus 
  





















[188, 296], a phenotype that is readily rescued upon re-introduction of RNAi resistant 
LEDGF/p75 (LEDGF BC) [204].  
 
Figure 4.3.2.8. Rescue of spreading HIV NL4.3 infection. The Q472L LEDGF/p75 mutation 
was tested for its ability to rescue spreading HIVNL4.3 infection in LEDGF/p75 knockdown 
cells [173]. HeLaP4/CCR5 cells (WT) and knockdown cells complemented with WT 
LEDGF/p75 BC were used as controls. A, Cells were infected in quadruplet with HIVNL4.3 at 
an MOI of 0.01. HIV replication was monitored by sampling the supernatant for p24 at regular 
time-points post infection. A representative HIV-1 breakthrough experiment is shown; B, 
HIVNL4.3 integration was measured by real-time quantitative PCR in the same experiment as 





In a similar setting, we complemented potent knockdown cells (KD) with the Q472L variant 
(LEDGF BC Q472L). LEDGF BC and the LEDGF BC Q472L supported HIV-1 replication to 
the levels observed for wild-type cells (WT) (fig. 4.3.2.8A). In parallel, we quantified 
integrated proviral copies. The nine-fold decrease in integrated proviral copies observed in 
KD cells was rescued to near wild-type levels in cells complemented with either LEDGF BC 
or the Q472L mutant (fig. 4.3.2.8B).  
 
4.3.3 Discussion and Conclusions 
LEDGF/p75 has been shown to promote HIV-1 replication in vitro [160, 171, 186-188, 201, 
202, 290, 291]. In this study, we have investigated the association between genetic variation 
in the PSIP1 gene and susceptibility to HIV-1 infection and disease progression in two South 
African HIV-1 cohorts. We found that, the rs2277191A, was associated with higher likelihood 
of HIV-1 acquisition. The rs2277191A was also associated with lower levels of CD4+ T cell 
counts during the early chronic phase of infection and rapid CD4+ T cell depletion, reflecting 
an early stage of disease progression in CAPRISA AI 002 cohort. However, rs10283923 
deviated from the frequencies expected under the Hardy Weinberg equilibrium. Genotyping 
was repeated to eliminate genotyping error as a reason for rs10283923 not to conform to the 
Hardy Weinberg expectations and interestingly, genotypes obtained were consistent between 
duplicates and free of contamination as the negative controls did not amplify.  
 
The rs12339417C was associated with higher CD4+ T cell count and lower viral load during 
the early chronic phase of infection in the CAPRISA AI 002 cohort. We further found that the 
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SNP rs12339417 had an influence on LEDGF/p75 mRNA expression levels. The 
rs12339417C was associated with lower levels of LEDGF/p75 mRNA expression. These 
findings suggest that the variation at the SNP rs12339417 locus inhibits HIV-1 replication.  
 
The interpretation of the CAPRISA AI 002 data was complicated by the small sample size of 
the study cohort. We therefore extended our analysis to a larger cohort, the Sinikithemba 
cohort, within the same geographical area, in order to get a clearer sense of the role of 
PSIP1 genetic variants in HIV-1 pathogenesis. We excluded rs10283923 and rs1033056 
from the analysis in the Sinikithemba cohort because these two SNPs showed no association 
with CD4+ T cell count during primary infection and rs10283923 did not conform to the 
frequencies expected under HWE in the CAPRISA AI 002 cohort.  Three SNPs (rs2277191, 
rs12339417 and rs61744944) were therefore selected for analysis in the Sinikithemba cohort. 
Sinikithemba cohort is comprised of chronically HIV-1 infected individuals whose date of 
infection is unknown and this made it impossible to study the effect of PSIP1 genetic 
variation on susceptibility to HIV-1 infection.   
 
Polymorphisms in the PSIP1 gene were not associated with either CD4+ T cell count or viral 
loads at baseline, which could be explained by the fact that individuals in this cohort were at 
different stages of HIV-1 infection upon enrolment into the study and immune activation [298, 
299]. The rs12339417C was significantly associated with delayed disease progression as 
was reflected by a slower rate of CD4+ T cell decline in the Sinikithemba cohort. The 
protective effect of the rs12339417C was consistent between the CAPRISA AI 002 and the 
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Sinikithemba cohort suggesting that a nucleotide change at the SNP rs12339417 locus 
maybe associated with inhibition of HIV-1 replication.  
 
Lastly, we investigated the association between the PSIP1 genetic variation and mRNA 
expression levels of LEDGF/p75 and found that rs12339417 influenced the expression of 
LEDGF/p75 with the rs12339417C significantly associated with lower levels of LEDGF/p75 
mRNA.  Seroconverters had significantly higher LEDGF/p75 mRNA levels compared to 
nonseroconverters at baseline. However, HIV-1 infected individuals expressed significantly 
lower levels of LEDGF/p75 mRNA compared to uninfected individuals. These findings 
suggested that high levels of LEDGF/p75 mRNA might be associated with a higher likelihood 
of HIV-1 acquisition and this corroborates the role of LEDGF/p75 as a cellular cofactor of 
HIV-1 infection in patients.  
 
Previous studies on human genes APOBEC3G [268] and TRIM5α (TRIM5αhu) [276] showed 
that the mRNA of these two genes is down-regulated in HIV-1 infected PBMCs, compared 
with uninfected PBMCs. Both APOBEC3G and TRIM5αhu are intrinsic antiviral factors. Here 
we extend these studies to a cellular cofactor of HIV-1 replication. We investigated whether 
HIV-1 infection was associated with dysregulation of LEDGF/p75 expression. However, no 
significant difference was observed in the median level of LEDGF/p75 expression between 




Although median levels of LEDGF/p75 mRNA did not reach statistical significance, they 
varied relatively throughout primary HIV-1 infection showing reduced levels of LEDGF/p75 
mRNA post infection. We therefore examined the kinetics of LEDGF/p75 mRNA expression 
in matched HIV-1 - negative and – positive samples obtained from 13 individuals who 
acquired HIV-1 infection during follow-up.  
 
PBMCs of these participants were available at baseline (before infection), within 3 months 
after infection (during the acute phase), and between 3 and 12 months after infection (during 
early chronic phase). The LEDGF/p75 mRNA expression levels were not significantly 
different among the different time points although there was an overall trend of decreased 
levels of LEDGF/p75 after infection. However, LEDGF/p75 mRNA expression levels 
fluctuated at the individual participant level, with 10 individuals showing a decrease and three 
showing an increase in LEDGF/p75 expression level after infection. 
 
Our findings demonstrate, for the first time, that genetic variation of PSIP1 may influence 
susceptibility to HIV-1 infection and the disease progression, which provide in vivo evidence 
that LEDGF/p75 is an important host cofactor for HIV-1 replication. Participants who 





Differential expression of LEDGF/p75 was associated with the SNP rs12339417 where the 
rs12339417C was showing significantly reduced mRNA levels of LEDGF/p75. This 
rs12339417C showed a slower rate of CD4+ T decline in the Sinikithemba cohort suggesting 
that HIV-1 replication is inhibited by lower levels of LEDGF/p75 in a cell, which confirms the 
previous in vitro study [201]. These results suggest that repressing LEDGF/p75 mRNA levels 






















The role of CypA, TRN-SR2 and LEDGF/p75 in promoting HIV-1 replication has been well 
established through extensive in vitro experiments [32, 134, 135, 160, 161, 171, 187, 201, 
202, 273]. In addition to in vitro studies, the role of CypA has been studied in vivo using 
populations from the developed world [61, 73, 74]. In this study, we investigated the 
association of genetic variation in the PPIA, TNPO3 and PSIP1 genes with susceptibility to 
HIV-1 infection and disease progression in South African cohorts.  
 
The minor allele (G) of SNP A1650G (1650G) in the promoter region of PPIA was 
significantly associated with lower CD4+ T cell count and higher viral loads during HIV-1 
primary infection. These findings suggest that the 1650G was associated with enhanced HIV-
1 replication as reflected by significantly higher viral loads and lower CD4+ T cell counts 
during primary infection in the CAPRISA AI 002 cohort. These findings are consistent with 
the data obtained from Swiss Caucasian HIV-1 cohort, where the 1650G was reported to be 
associated with a rapid CD4+ T cell depletion [61]. A trend towards association between 
1650G  and rapid CD4+ T cell depletion was reported among African American [73]. 
Therefore, in this study we tested the effect of the 1650G on clinical outcomes upon HIV-1 
exposure in black South Africans (CAPRISA AI 002 cohort) and our results showed a 
borderline association between rapid CD4+ T cell depletion and the 1650G. Lack of 
significant results in our study could be attributed to a small sample size with only 24 HIV-1 
positive participants who had the 1650G in the CAPRISA AI cohort.  
 
The 1650G in the promoter region of the PPIA gene was significantly associated with 
elevated levels of CypA mRNA expression post HIV-1 infection, suggesting that the 1650G 
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promotes HIV-1 replication in vivo and rapid disease progression by inducing higher 
expression of CypA mRNA levels. Pre-HIV-1 infection levels of CypA mRNA expression were 
significantly higher in PBMC genotyped for the 1650G compared to PBMC harboring wild 
type genotyped (AA) at the SNP locus. This could suggest that 1650G might be indirectly 
associated with susceptibility to HIV-1 infection. Results obtained from the ex vivo 
experiment in this study suggested that CypA mRNA expression might be dysregulated by 
HIV-1 infection. This was evident from the observation that there was a sudden drop in CypA 
mRNA expression levels upon HIV-1 infection and CypA mRNA levels were restored to 
significantly higher levels after a week post HIV-1 infection. The 1650G might be directly 
involved in promoting proper uncoating of HIV-1 capsid to make RNA genome available for 
reverse transcription to take place in order to synthesize viral copy DNA (cDNA).  
 
Following cDNA synthesis, viral cDNA has to be integrated into the host chromosome which 
resides within the nucleus which is separated from the cytoplasm by a double lipid bilayer. 
Therefore HIV-1 relies on import proteins such as TRN-SR2 for nuclear import [160]. 
Numerous in vitro studies have shown that TRN-SR2 is an important HIV-1 cofactor [32, 67, 
160, 161], however, this has not been shown in vivo. In this study, we undertook a systematic 
investigation of the association of SNPs in the TNPO3 gene with susceptibility to HIV-1 
infection and disease progression in two South African HIV-1 cohorts.  
 
The minor allele (G) of rs1154330 (rs1154330G) in intron 12 of the TNPO3 gene was 
associated with faster acquisition of HIV-1 infection, higher viral load and lower CD4+ T cell 
count in the CAPRISA AI 002 cohort. However, rs1154330G was not associated with disease 
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progression in the CAPRISA AI cohort probably due to a small number of HIV-1 positive 
participants (13 out of 52 participants) who carried rs1154330G. Therefore the analysis of the 
rs1154330G was extended to the Sinikithemba cohort comprising 450 HIV-1 chronically 
infected participants from the same geographical area. Since the Sinikithemba cohort is a 
seroprevalent cohort with unknown dates of infection, the influence of the rs1154330G could 
only be assessed on CD4+ T cell levels and viral loads at study enrollment (baseline) and on 
the trajectory of CD4+ T cell decline over the 5 years of follow-up  
 
Interestingly, the rs1154330G was significantly associated with a faster rate of CD4+ T cell 
decline in the Sinikithemba cohort. The results obtained from the Sinikithemba cohort were 
consistent with the data obtained from the CAPRISA AI 002 cohort suggesting that the 
rs1154330G gives HIV-1 selective advantage for efficient replication and productive infection 
in the South African population. The effect of the rs1154330G could not be assessed on the 
protein functionality of TNR-SR2 protein because this SNP is located in the intron region of 
the TNPO3 gene. It is therefore presumed that the rs1154330G is associated with TRN-SR2 
mRNA expression levels, regulation of possible splice variants or post-translational protein 
modifications. At baseline, in the Sinikithemba cohort, the rs1154330G was associated with 
neither CD4+ T cell count nor viral loads. This lack of association could be attributed to the 
fact that participants in the Sinikithemba cohort were recruited while they were at different 
stages of HIV-1 infection.  
 
In addition to the SNP rs1154330, there were other SNPs in the TNPO3 gene that were 
associated with clinical outcomes in the CAPRISA AI 002 cohort. However, these SNPs did 
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not show consistent association with clinical outcomes during primary infection. The minor 
allele (A) of rs2305325 (rs2305325A) was associated with higher CD4+ T cell counts but not 
with viral loads during HIV-1 primary infection. The association between the rs2305325A and 
higher CD4+ T cell counts may probably be due to alterations in the cytokine milieu such as 
variation in IL-7 effect since the levels of CD4+ T cell counts were similar between 
participants carrying the wild type genotype and mutant genotype prior to HIV-1 infection. On 
the other hand, the minor allele (A) of the SNP rs35060568 (rs35060568A) was associated 
with higher viral load during the primary infection. However, the rs35060568A was only 
associated with lower CD4+ T cell counts during the early chronic phase of infection.  
 
The minor allele (C) of rs6957529 (rs6957529C) showed inconsistent association with both 
viral loads during primary infection, where it was associated with lower viral load during acute 
phase of infection and higher viral load during the early chronic phase of infection. The 
plausible explanation for this could be that the virus developed the escape mutation in the 
later stages of infection in order to overcome the inhibiting effect of the rs6957529C. The 
minor allele (C) of rs10229001 was associated with higher CD4+ T cell counts and lower viral 
load during the early chronic phase of infection only. To the best of our knowledge this study 
demonstrated for the first time that the genetic variants in the TNPO3 gene are associated 





LEDGF/p75 has been shown to play a central role in promoting HIV-1 replication in vitro 
[171, 187, 189, 197, 201, 202, 291]. In this study, we investigated the association between 
genetic variation in the PSIP1 gene and clinical outcomes. As the preliminary study, we 
screened part of the C-terminal region of the PSIP1 gene which included the IBD in order to 
identify SNPs that could attenuate HIV-1 infection. The preliminary study was done only in 
fewer individuals (n = 126) from CAPRISA AI 002 cohort. Sequencing revealed 14 previously 
described SNPs, 13 of which were allocated in the intron regions of the PSIP1 gene and one 
SNP rs61744944 was located in exon 13 outside the IBD of the PSIP1 gene though. The 
SNP rs61744944 is a non-synonymous SNP resulting in an amino acid change (Glutamine to 
Leucine) at position 472 of LEDGF/p75 (Q472L).  
 
The preliminary analysis revealed an association between the minor allele (T) of the SNP 
rs61744944 (rs61744944T) and increased susceptibility to HIV-1 infection. Surprisingly, the 
rs61744944T was associated with consistently higher CD4+ T cell counts and lower viral 
loads post HIV-1 infection. Consequently, the analysis of the rs61744944T was therefore 
extended to a larger number (n = 247) of participants from the same cohort in order to 
elucidate its role in HIV-1 infection. In addition to this SNP four additional intronic haplotype 
tagging (ht) SNPs were analyzed in these 247 participants from CAPRISA AI 002 cohort. It is 




Interestingly, the minor allele (A) of the ht SNP rs2277191 (rs2277191A) was found to be 
associated with higher likelihood of HIV-1 acquisition, lower CD4+ T cell counts during the 
early chronic phase of infection and rapid CD4+ T cell depletion in CAPRISA AI002 cohort.  
 
Whereas the minor allele (C) of the other ht SNP rs12339417 (rs12339417C) was associated 
with higher CD4+ T cell count and lower viral load during the early chronic phase of infection 
in the CAPRISA AI 002 cohort. Although the rs61744944T was not associated with higher 
CD4+ T cell counts in these 52 HIV-1 positive participants, the rs61744944T was consistently 
associated with lower viral load during primary infection. Therefore SNPs rs2277191 and 
rs12339417 were further analyzed in a larger chronic infection Sinikithemba cohort based on 
their association with CD4+ T cell counts during the early chronic phase of infection. The 
rs61744944 was included in this analysis based on the preliminary findings that suggested 
an association with clinical outcomes and based on the fact that this was the only exonic 
SNP in the PSIP1 gene that was analyzed in this study. 
 
The Sinikithemba cohort comprises chronically HIV-1 infected individuals with unknown date 
of infection and therefore we assessed the effect of these three SNPs on trajectory of CD4+ T 
cell decline over 6 years of follow-up. The rs12339417C was associated with delayed 
disease progression as was reflected by significantly a slower rate of CD4+ T cell decline in 
the Sinikithemba cohort. The protective effect of the rs12339417C was consistent between 
the CAPRISA AI 002 and Sinikithemba cohorts suggesting that the rs12339417C may be 




In an attempt to elucidate the mechanism that the rs12339417C used to inhibit HIV-1 
replication, we investigated the association between the rs12339417C and LEDGF/p75 
mRNA expression levels. The other two SNPs rs2277191 and rs61744944 were also 
included in this analysis. Interestingly, the rs12339417C was associated with lower 
expression of LEDGF/p75 mRNA levels suggesting that the rs12339417C inhibited HIV-1 
replication through suppressing the mRNA levels of LEDGF/p75 in vivo. These findings are 
consistent with in vitro knockdown studies [67, 296]. The PBMCs obtained from 
seroconverters had higher mRNA expression levels of LEDGF/p75 compared to 
nonseroconverters suggested that high levels of LEDGF/p75 may increase the likelihood of 
HIV-1 acquisition and the rate of disease progression. This observation is consistent with 
findings that LEDGF/p75 is indeed an important HIV-1 replication cofactor [201]. The other 
two SNPs, rs2277191 and rs61744944 were neither associated with disease progression in 
the Sinikithemba cohort nor with mRNA expression levels of LEDGF/p75 in the CAPRISA AI 
002 cohort. 
 
Lastly, we analyzed the impact of the mutant LEDGF/p75 (Q472L) on LEDGF/p75-IN 
interaction and plausible effects on cellular binding factors of LEDGF/p75, JPO2 and pogZ. 
The mutation Q472L did not alter the binding affinity of LEDGF/p75 for IN, JPO2 and pogZ. 
The back complementation of LEDGF/p75-depleted cells with the Q472L rescued HIV-1 
replication to near wild-type levels suggesting that Q472L did not alter the functionality of 
LEDGF/p75. Lack of association between Q472L and binding affinity of LEDGF/p75 for IN, 
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JPO2 and pogZ could be explained by the fact that Q472L occurs outside the IBD of 
LEDGF/p75. However, it is not inconceivable that this mutation may affect other LEDGF/p75 
functions such as integration site targeting.  
 
As discussed above, this study extended genetic association studies in HIV-1 research from 
immunological factors or proteins involved in the immune response to HIV-1 replication 
cofactors. The novel aspect of this study was this study was conducted in a population from 
Sub-Saharan Africa, South Africa in particular which is heavily burdened by HIV-1 epidemic.  
 
It is interesting to note that these SNPs were not found to be important in HIV-1 pathogenesis 
in previous studies that used genomewide association study approach [300, 301]. The 
reasons for this could include ethnic differences in allele frequencies because they were 
studied in non-African populations. Other reasons could be cohort design and phenotype 
used, Pereyra et al. looked at elite controllers [301] and Petrovski et al. looked at viral set 
point in African Americans [302], respectively. The other plausible reason could be that the 
effect of genetic variation within HIV-1 replication cofactors on HIV pathogenesis is modest 









This study provides in vivo evidence that CypA, TRN-SR2 and LEDGF/p75 are crucial 
replication cofactors for efficient HIV-1 replication, which has been well established through 
extensive in vitro experiments [32, 134, 135, 160, 161, 171, 187, 201, 202, 273]. 
 
This study had two significant limitations: (1) there were few individuals with HIV-1 primary 
infection whose date of infection was known and; (2) The date of infection was not known for 
HIV-1 chronically infected individuals, and therefore the clinical data of these individuals 
could not to be categorized and analyzed according to the different phases of HIV-1 infection. 
The acute phase of infection is characterized by spike in viral load whereas, at viral set point, 
the viral load drops and at the chronic phase of infection, high viral loads resume. HIV-1 
chronic infection cohort made it difficult to assess the influence of genetic variations at 
baseline (study entry) because participants in this study cohort were at different stages of the 
disease when they were recruited into this cohort. 
 
Despite the challenges mentioned above, the results of this study suggest genetic variation in 
these select HIV-1 replication cofactors may be associated with susceptibility to HIV-1 
infection and disease progression. Although the association between genetic variant A1650G 
of CypA and HIV-1 disease outcomes has been previously reported in populations from the 
developed countries [61, 73, 74], this is the first study to show this association in the 
population from developing world which is heavily burden by HIV-1 epidemic. Furthermore, 
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this is the first study to report the association of genetic polymorphisms in the TNPO3 and 
PSIP1 genes with susceptibility to HIV-1 infection and disease progression, confirming that 
TRN-SR2 and LEDGF/p75 are indeed important HIV-1 replication cofactors. This study 
suggests that targeting protein-protein interactions (PPIs) between HIV-1 and replication 
cofactors could be a new antiviral target against which small-molecule protein-protein 
interaction inhibitors (SMPPIIs) could be designed to inhibit HIV-1 infection. However, due to 
small sample size and heterogeneous nature of our cohorts, our findings should be 
interpreted with caution and will need to be replicated in additional studies. 
 
Future studies should investigate the association of genetic variation in other replication 
cofactors with HIV-1 clinical outcomes. Future studies should also include more studies to 
understand mechanisms of viral interaction with HIV replication cofactors and design of 
therapeutic interventions targeting replication cofactors and whether the effectiveness of 
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